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INTRODUCTION 
 
In 2002, the National Kidney Foundation (NKF) published the Kidney 
Disease Outcomes Quality Initiative (KDOQI) Clinical Practice 
Guidelines for Chronic Kidney Disease: Evaluation, Classification, and 
Stratification. These clinical practice guidelines expanded the focus of 
chronic kidney disease (CKD) management from end-stage renal disease 
(ESRD) to the entire spectrum of kidney disease, from early kidney 
damage through to kidney failure. Guidelines, prior to this, primarily 
addressed hundreds of thousands patients with ESRD who were receiving 
dialysis. The goal of increasing the scope of diagnosis of Chronic Kidney 
Disease and identifying patients earlier in the course of the disease when 
treatment could potentially prevent the loss of kidney function and slow 
the progression of the disease. 
   These guidelines have had a substantial effect on clinical 
practice and as a result Chronic Kidney Disease is now identified much 
earlier in the disease process. Additionally, as the publication of these 
guidelines, several epidemiological studies have deter- mined the 
associations of Chronic Kidney Disease with adverse health outcomes in 
the general population, further highlighting the public health importance 
of Chronic Kidney Disease. 
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 However, an unintended consequence of these efforts is that a very 
high percentage of older adults are being identified as having Chronic 
Kidney Disease.  
 The care for older adults with Chronic Kidney Disease, or geriatric 
nephrology, has gained recent attention and has become a focus of 
epidemiological research studies. With the increase in percentage of 
elderly population the prevalence of chronic Kidney Disease has 
increased and is expected to increase in the future. Further, it is important 
to emphasize that ageing kidney with decreasing glomerular filtration rate 
is different from diseased kidney with decreased glomerular filtration rate 
in that the diseased kidney suffers more complication. However the 
incidence of complications in the diseased kidney is substantially more 
than in the younger population. Not only are the complications specific to 
Chronic Kidney Disease are increased but also non specific disease 
conditions such as functional decline, cognitive impairment, fragility 
finds increased incidence in this subset of population.  
 In this study we analyze the spectrum of presentation of chronic 
kidney disease in the older population.
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AIMS & OBJECTIVES 
 
1. To analyze the spectrum of chronic kidney disease in the elderly 
population. 
2. To analyze the etiology, duration, stage of the CKD and serum 
creatinine at presentation. 
3. To look into the presence of smoking and alcohol consumption  
4. Functional and nutritional assessment of the geriatric population 
including body mass index, frailty, falls, incontinence and dementia. 
5. To analyze the presence of various acute and chronic complications of 
chronic kidney disease at presentation such as acute on chronic kidney 
disease, acute pulmonary edema, anemia, acidosis, hyperkalemia, 
hyponatremia, encephalopathy, pericarditis and correlate the occurrence 
of these complications with advancing stage of CKD 
6. To quantify the ejection fraction, analyze ECG and chest X ray in the 
geriatric CKD population. 
7. To analyze abnormalities in urinalysis and presence of viral markers 
and special investigation (if any done) 
8. To analyze the mode, center, frequency, funding for renal replacement 
therapy 
9. To observe and compare the follow up in patients from rural and urban 
population 
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REVIEW  
 
OF  
 
LITERATURE 
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“Chronic kidney disease is defined as abnormalities of kidney structure or 
function, present for more than 3 months, with implications for health. 
These include the following. 
(a)Markers of kidney damage - Albuminuria (AER ≥ 30mg/24 h; ≥ 30 
mg/g [≥ 3 mg/mmol]), urine sediment abnormalities, electrolyte and other 
abnormalities caused by tubular disorders, abnormalities detected through 
histology, Structural abnormalities detected through imaging, history of 
renal transplantation. 
(b) Decreased GFR <60 ml/min/1.73m2 
as defined by National Kidney Foundation - KDIGO 2012 clinical 
practice guidelines for evaluation and management of chronic kidney 
disease”1 
 
 Prior to the definition for chronic kidney disease introduced and put 
forth by the National Kidney Foundation (NKF) Kidney Disease 
Outcome Qualitative Initiative (KDOQI) in 20022, problems pertaining to 
end stage renal disease were of major concern. This definition opened up 
new avenues and widened the perspective towards chronic kidney 
disease, focusing not only on the end stage renal disease, but also on the 
wider spectrum encompassing various stages of Chronic kidney disease. 
In doing so, the management in chronic kidney disease experienced a 
paradigm shift, now focusing on the prevention and retarding the further 
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progression of kidney disease, addressing complications earlier than 
before, preparing the patient for renal replacement therapy and renal 
replacement therapy. 
 
 In view of the difficulties associated with glomerular filtration rate 
measurement using radioactive isotopes and the difficulty associated with 
the 24 hour urinary collection, it is recommended that the glomerular 
filtration rate be estimated (eGFR) by using formulas and this eGFR has 
been incorporated into the staging system for chronic kidney disease. 
This staging system has been used in the clinical decision making and in 
guideline updates. Though the eGFR was most commonly estimated 
using the modification of diet in renal diseases (MDRD), Chronic kidney 
disease Epidemiology Collaboration (CKD - EPI) equation has fallen into 
favour after its recommendation by the KDIGO3. 
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 The staging of CKD as recommended by KDIGO, 
 
!
 
“Table 1. GFR category in staging 
*Relative to young adult level 
GFR category G1 and G2 does not fulfill the criteria for CKD without 
any other evidence for kidney damage 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
!
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Table!2.!Albuminuria!category!in!staging!
!
*Relative to young adult level. 
**Including nephrotic syndrome (albumin excretion usually >2200 mg/24 
hours [ACR 42220 mg/g; 4220 mg/mmol])”!!
!
!
!
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“Table 3. Staging of CKD. Green is low risk (no CKD if there are no 
other markers of kidney damage); Yellow is moderately increased risk; 
Orange is high risk; Red is very high risk.”1 
!
!
!
ETIOLOGY 
 The various aetiologies for chronic kidney disease are diabetic 
nephropathy, chronic glomerulonephritis, hypertension associated chronic 
kidney disease, ADPKD and other cystic kidney diseases and 
tubulointertial diseases. The predominant cause in a population depends 
on the geographic area.  In a patient who is newly diagnosed with chronic 
kidney disease and hypertension first time and no obvious causes for 
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glomerular and tubulointerstitial disorder could be made out, then it is 
probably due to hypertension 
!
!
CLINCAL PRESENTATION 
 
 Patients present with symptoms only in stage 4 or 5 of CKD. 
Preceding which patients are usually asymptomatic and present with 
either symptoms and complications pertaining to systemic disease 
process or cardiovascular complications and other complications of CKD. 
Patients with chronic kidney disease may succumb to cardiovascular 
complications even before they progress into the advanced stages of 
chronic kidney disease. However there is no current recommendation for 
screening of general population for chronic kidney disease. Though 
certain guidelines recommend screening of special group of population to 
detect CKD in the early stages.4 
 
 
RETARDING THE PROGRESSION OF CHRONIC KIDNEY 
DISEASE: 
 “An important step in the management of CKD is retarding the 
progression of disease. This includes blood pressure control, glycemic 
control, anti-proteinuria agents (ACE inhibitors and ARB) and dietary 
restrictions apart from specific treatment of the  underlying disease that is 
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the source for kidney disease. 
 The degree of hypertension in CKD is associated with the rate of 
loss in renal function. Controlling the blood pressure retards the loss in 
renal function. Until recently, lower targets for blood pressure was set for 
the CKD population with hypertension as compared to the general 
hypertensive population. However in the recent turn of events it is now 
focussed on less intensive and individualised targets for patients with 
CKD5. JNC 8 recommends the target blood pressure in CKD patients with 
hypertension to be 140/90 mmHg. The pharmacotherapy should focus on 
the cardiovascular risk, other comorbidities and the treating physician 
should be considerate on the side effects of the drug in the patients being 
used. The blood pressure recorded at clinic can be falsely elevated in 30% 
patients who are normotensive and 40% patients who are tagged 
adequately controlled are recorded to have elevated levels of blood 
pressure at home. Hence when possible home based blood pressure 
monitoring should be done if the patient prefers.  
 ACE inhibitors and ARBs stand the first line therapy in patients with 
CKD and hypertension. They exert benefit by anti- hypertensive effect, 
anti- proteinuric effect and also by exerting beneficial effect on 
cardiovascular system. Usually multiple drugs are required for the 
optimal control of the blood pressure in CKD patients. However it is 
recommended by the KDIGO 2012 guidelines that ACE inhibitors, ARBs 
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and other nephrotoxic agents including potassium sparing diuretic, 
NSAIDs be spared from use in patients with acute on chronic kidney 
disease and hyperkalemia.  
 If adequate control of blood pressure is not achieved, a second drug 
may be added. If 24 hour urinary PCR is <0.6, then amlodipine may be 
used. If the 24 hour urinary PCR >0.6, a non dihydropyidine calcium 
channel blocker such as diltiazem may be used. This is based on the 
evidence that amlodipine causes peripheral vasodilation and increases 
renal blood flow increasing intra- glomerular pressure and hence 
increasing the proteinuria. If further adequacy of blood pressure control is 
required, the addition of diuretic as the third line is beneficial. The choice 
of diuretic depends on the patient characteristic and should be tailored to 
the serum creatinine, salt intake, diabetic status, arrhythmia and 
cardiomyopathy concerns. A detailed investigation for secondary causes 
of hypertension is required if 3 drug regimen does not provide blood 
pressure control. Beta blockers can be added along the treatment course 
as when they are indicated for ischemic cardiac disease and arrhythmia. 
However their role in treatment of hypertension has been questioned due 
to the wide array of metabolic disturbances it produces.”7  
 Obesity and malnutrition being varied ends of a spectrum has wide 
implications in patients with CKD. Obesity advances the rate of 
progression of CKD. Hence, early in CKD when obesity may be present, 
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weight reduction is advisable. However as the CKD progresses, 
malnutrition is more common. Malnutrition occurs due to loss of appetite 
causing poor dietary intake, poor absorption of nutrients in a uremic gut, 
inflammation, oxidative stress, acidosis, and protein loss in the urine. In 
CKD patients restriction of proteins to 0.8 g/kg/day in patients with GFR 
<30 ml/min/1.73 m2 retards the progression of CKD. However it is 
essential to be watchful as these patients are prone to develop 
malnourishment from multitude of causes as mentioned earlier which 
may be accentuated by the protein restriction. A major step in 
development of hypertension in patients with CKD is retention of salt and 
water. Hence restriction of sodium should be less than 5 g/day of sodium 
chloride. Water intake should be optimised to avoid volume overload and 
volume depletion. Potassium containing diet should be avoided for fear of 
hyperkalemia.8 
 
REFERRAL TO A NEPHROLOGIST: 
 Referral to a nephrologist is suggested in the following:4, 9 
1.! CKD in advanced stages including the Category G4 and Category G5 
CKD. 
2.! Persistent proteinuria with urinary albumin creatinine ratio ≥ 300 mg/g. 
3.! Red blood cells more than 20/ hpf which is not explainable 
4.! Worsening of CKD as established by either a sustained decrease in the 
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estimated GFR of more than 5 ml/ min/ 1.73 m2 in a year or more than 
25% drop in estimated GFR from the recorded baseline.  
5.! The hypertension in a CKD patient being resistant to the treatment 
combination of four or more drugs. 
6.! Inherited kidney disease 
7.! Recurrent nephrolithiasis 
8.! Extensive nephrolithiasis 
9.! Abnormalities in serum potassium that are persistent 
10.! Suspected stenosis of the renal artery 
 
 
ACUTE ON CHRONIC KIDNEY DISEASE: 
 Whenever there is rapid rise in creatinine due to rapid loss in renal 
function, it can be due accelerated damage induced by underlying disease 
or a superimposed injury. Superimposed insult in chronic kidney disease 
can be due to volume reduction, drug induced insult, contrast induced 
injury, renal infections and systemic intercurrent illness, electrolyte 
disturbances such as hypercalcemia, decreased cardiac output, 
tachyarrythmias, obstructive uropathy, renal vein thrombosis, ischemic 
nephropathy. Volume reduction results due to gastrointestinal loss and 
excessive diuresis.  
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INITIATION OF RENAL REPLACEMENT THERAPY: 
 Generally it is necessary to plan the appropriate mode of renal 
replacement therapy (RRT) in patients with eGFR <20 ml/min/1.73m2 
and/or whom there is rapid progression in the loss of renal function. The 
mode of RRT should be discussed and planned with the patient, that is 
suited for his life. It has to be planned earlier before the actual 
requirement as mentioned above. A patient planned for hemodialysis, it 
takes 8-12 weeks for the AV fistula to mature. A patient planned for 
peritoneal dialysis, it takes time to heal and for appropriate education 
regarding the peritoneal dialysis. Since early renal transplantation has 
better outcome and results, it is essential to initiate in the waiting list 
before initiation of dialysis10. The possibility of a prospective living donor 
needs to be considered before initiating the patient on dialysis.  
 Initiating a dialysis early in the progression of CKD is not associated 
better surviva11 . Hence it is essential to start renal replacement therapy as 
per KDIGO clinical guidelines. It is indicated when patients symptoms 
and signs are explainable by the failing kidney. These include  
1. Acid-base and electrolyte abnormalities  
2. Serositis,  
3. Uncontrolled volume overload status  
4. Uncontrolled hypertension 
5. Worsening nutritional state despite intervention  
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6. Pruritus 
7. Cognitive impairment 
 These complications positively correlate when the eGFR drops to 
less than 15 ml/min/1.73m2 
 
 The common etiologies in the causation of CKD depends on 
population being studied. However the most common causes include 
diabetes mellitus, chronic glomerulonephritis. Chronic interstitial 
nephritis. However in developing country like India diabetes mellitus 
remains the most common cause of chronic kidney disease 
 
IMPACT OF DIABETES ON KIDNEY 
 Diabetic nephropathy has been reported as complications in patients 
with Type 1 diabetes mellitus, Type 2 diabetes mellitus and other causes 
of diabetes also resulting from endocrine insufficiency due to a pancreatic 
disorder such as chronic pancreatitis or after a pancreatectomy. This 
implies a chronic elevation of glycemic levels in the blood for a sufficient 
period of time is ample and as well essential in the development of 
diabetic nephropathy 
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EPIDEMIOLOGY OF DIABETIC NEPHROPATHY 
 In type 1 diabetes mellitus the evolution of diabetes mellitus over the 
course has been well characterized. Usually a 20-30% of the patients with 
Type 1 Diabetes mellitus will progress to develop moderately increased 
proteinuria ( previously termed as microalbuminuria). Under 50% of the 
patients with moderately increased proteinuria progress on to severely 
increased albuminuria (previously termed macroalbuminuria). The 
moderately increased albuminuria usually heralds the development of 
severely increased albuminuria. However severely increased albuminuria 
might not herald the development of advanced nephropathy with 
glomerular filtration rate of <60 ml/min/1.73m2. Patients with severely 
increased albuminuria may have any of the following course. The 
proteinuria may progressively increase and progress to reduction in GFR. 
The severely increased albuminuria may stay the same or regress to 
moderately increased albuminuria or even less than moderately increased 
albuminuria (<30mg/day)12-14. Before the institution of tight glycemic 
control and the use of ACE inhibitors, the prevalence of albuminuria, 
overt nephropathy, advanced kidney disease and end stage renal disease 
were high. A high incidence of upto 25% to 45% of patients developing 
overt nephropathy with ESRD developing in upto 17% of the patients. 
However with the strict glycemic control and the use of ACE inhibitors, 
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the prevalence of overt nephropathy and ESRD has reduced15-20. The risk 
of developing severely increased proteinuria usually occurs between 10 to 
15 years and in <1% of the patients between 20 to 25 years. Hence a 
patient developing proteinuria for the first time after 20 to 25 years of 
having no proteinuria, non diabetic causes of kidney disease needs to be 
ruled out. 
 Data suggest that the risk of nephropathy is equal in both Type 1 and 
Type 2 diabetes mellitus. This is based on Ritz et al, 1999 that the 
progression from onset of diabetes mellitus to proteinuria and from 
proteinuria to ESRD is the same in Type 1 and Type 2 diabetes mellitus 
21,21. As is the case with Type 1 DM, optimal glycemic control with use of 
ACE inhibitors, moderately increased albuminuria can regress retarding 
the progression and may even prevent the development of overt 
nephropathy. “The occurence of moderately increased albuminuria, 
severely increased albuminuria, and either increased plasma creatinine 
(defined as ≥2.0 mg/dL) or requirement for renal replacement therapy 
was 25, 5, and 0.8 percent, respectively at 10 years of follow up ashown 
in the UKPDS study.”23   
 
PATHOGENESIS: 
In the pathogenesis of diabetic nephropathy, various parameters play role. 
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The contribution from the intraglomerular hypertension due to 
renovascular involvement by the disease process is evident from the use 
of drugs such ACE inhibitors which decrease the intraglmerular 
hypertension25. 
 Hyperglycemia has a multitude of effects in the development of 
diabetic nephropathy. The increased glucose causes glycation of the 
mesangial matrix protein which results in mesangial expansion and 
apoptosis of the mesangial cell. The increased glucose in the circulation 
causes a non enzymatic glycation of the circulating and tissue aminoacids 
resulting in the formation of Advanced glycation end product. The AGEP 
bonds with collagen while it gets deposited in the kidney resulting in 
microvascular complications27-29, 31. Hyperglycemia also plays role by 
increasing the activation of protein kinase C and increased expression of 
heparanase increases the permeability of the filtration membrane to 
albumin. 
 Increased plasma prorenin activity, increased cytokines including 
VEGF, TGF beta, impaired expression of nephrin and defective podocyte 
specific insulin signaling also play role in the development of diabetic 
nephropathy30. 
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Fig 4. AGE product formation in the pathogenesis of  diabetic 
nephropathy . 
 
RISK FACTORS: 
 Various risk factors contribute to the accelerated loss of renal 
function in a patient with diabetic nephropathy. Genetic factors play a 
role in the development of diabetic nephropathy. This is evident from the 
fact that incidence of diabetic nephropathy is increased in those patients 
with family history of diabetes mellitus. “Pettitt et al assessed the 
likelihood of the child developing proteinuria in two successive 
generation in Pima Indians. He found that the incidence of developing 
nephropathy was 14% if none of the parents had nephropathy, 23% if one 
of the parent had nephropathy and 46% if both the parents had 
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nephropathy”32. Studies that have examined the effect of ACE gene 
genotype has produced conflicting results. However DD polymorphism in 
the ACE gene has been associated with the increased risk of developing 
diabetic nephropathy33.  
  The association of age in the development of diabetic nephropathy 
is the increased occurrence of diabetic nephropathy as the age advances34. 
In patients with Type 1 DM, the risk of developing ESRD is cery low if 
diagnosed prior to the age 535. Poor glycemic control, African American 
race, increased duration of diabetes, obesity, oral contraceptives, 
smoking. Increased blood pressure are associated with increased risk of 
development of diabetic nephropathy. 
 
HISTOLOGY: 
 The histological examination of the renal tissue under light 
microscopy reveals measangial expansion and in advanced stages 
glomerular sclerosis. Examination under electron microscopy reveals 
glomerular basement membrane thickening. A nodular deposition of 
hyaline material in the arteriolar walls (Nodular Glomerulosclerosis) 
referred to as the kimmelstein Wilson lesion can also be detected. The 
prognostic implication of these lesions do not differ. 
“The classification proposed by the Renal Pathology Society is as 
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follows: 
Class I: Isolated glomerular basement membrane thickening. Basement 
membranes are greater than 430 nm in males older than age 9 and 395 nm 
in females. There is no evidence of mesangial expansion, increased 
mesangial matrix, or global glomerulosclerosis involving >50 percent of 
glomeruli. 
 
Class II: Mild (class IIa) or severe (class IIb) mesangial expansion. A 
lesion is considered severe if areas of expansion larger than the mean area 
of a capillary lumen are present in >25 percent of the total mesangium. 
 
 
Class III: At least one Kimmelstiel-Wilson lesion (nodular intercapillary 
glomerulosclerosis) is observed on biopsy and there is <50 percent global 
glomerulosclerosis. 
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Fig 5. Electron Microscopy of glomerulus in a patient with diabetic 
nephropathy showing increased thickening of the basement membranes. 
 
Class IV: Advanced diabetic sclerosis. There is >50 percent global 
glomerulosclerosis that attributable to diabetic nephropathy. 
 
The severities of interstitial and vascular lesions were also assigned 
scores: 
A score of 0 was assigned if the interstitium had no areas of interstitial 
fibrosis and tubular atrophy (IFTA); scores of 1, 2, or 3 were assigned if 
areas of IFTA <25, 25 to 50 or >50 percent, respectively. 
 
A score of 0 was assigned if no T lymphocytes or macrophage infiltrate 
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was present. Scores of 1 or 2 were assigned if infiltrate was limited to the 
area surrounding atrophic tubules, or if infiltrate was not limited, 
respectively. 
 
Scores of 0, 1, or 2 were assigned if no arteriolar hyalinosis, one arteriole, 
or more than one arteriole with hyalinosis was present. In addition, the 
most severely affected arteriole was assigned a score of 0, 1, or 2 if there 
was no intimal thickening, intimal thickening < thickness of media or 
intimal thickening > thickness of the media.”3 
 
Fig 6. Light microscopy of glomerulus showing hyaline thickening at the 
walls of the arteriole (arrow) with diffuse mesangial expansion. 
 
! 29!
 Other causes of nodular glomerulosclerosis are 
1.! Amyloidosis 
2.! Monoclonal immunoglobulin deposit disease, with majority due to kappa 
light chain deposit disease and other organized glomerular deposition 
disease 
3.! Fibrillary and immunotactoid glomerulonephritis 
4.! Fibronectin glomerulopathy  
5.! Collagen III glomerulopathy 
6.! Chronic hypoxic conditions including cyanotic congenital heart disease 
7.! Chronic ischemic conditions such as renal artery stenosis 
8.! Chronic membranoproliferative glomerulonephritis Type I 
9.! Idiopathic glomerulosclerosis the occurrence of which can be seen in 
smokers and hypertensive patients. It can also be seen in patients with 
metabolic syndrome without overt diabetes mellitus. 
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Fig 7. Light microscopy showing nodular (N) glomerulosclerosis in 
patients with diabetic nephropathy 
 
 
 
CLINICAL PRESENTATION AND LABORATORY 
FINDINGS: 
 The clinical presentation in diabetic nephropathy includes 
albuminuria and hematuria. The albuminuria in diabetic nephropathy can 
be rather moderately increased albuminuria or severely increased 
albuminuria. Moderately increased albuminuria heralds the occurrence of 
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severely increased albuminuria. However the degree of albuminuria in 
severely increased albuminuria poorly correlates with the progression of 
renal injury37. Despite a decreasing albuminuria the patient may progress 
to advanced kidney disease and may progress on to ESRD. But patients 
with the highest rate of severely increased albuminuria had the increased 
loss renal function38. The reason for progressive loss of renal function in 
diabetic patients without proteinuria is not known but it maybe attributed 
to the renovascular disease in such patients. However the resistance 
offered to blood flow in both proteinuric diabetic nephropathy and non 
proteinuric diabetic nephropathy as detected by renal duplex scan remains 
the same. The occurrence of such non proteinuric diabetic nephropathy is 
increased in the younger population in whom the prevalence of such 
renovascular involvement is less common. These above mentioned points 
argues against the renovascular involvement as a cause of renal disease 
progression in non proteinuric diabetic nephropathy 
 The presence of microscopic hematuria has been detected in diabetic 
nephropathy though the sediments in the urine may not be detected. 
However, hematuria in a diabetic individual can also be due to other 
glomerular disease such as membranous nephropathy, IgA nephropathy. 
The presence of microscopic hematuria in a series of evaluated patients 
was due to IgA nephropathy, membranous nephropathy and severe 
diabetic nephropathy39. Similarly, evaluation of a patient series with red 
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cell cast revealed IgA nephropathy in 2 patients, post infectious 
glomerulonephritis in 1 patient and diabetic nephropathy a the cause in 
other 5 patients40. 
 
DIABETIC NEPHROPATHY & DIABETIC 
RETINOPATHY – THE LINK: 
 Patients with Type 1 DM and diabetic nephropathy will have other 
associated microvascular complications such as retinopathy. The 
occurrence of retinopathy will precede the development of nephropathy. 
Combining the facts, a diabetic patient with renal involvement but 
without retinopathy, non diabetic causes of the renal involvement should 
be considered. However, the involvement of retina by the diabetes may 
occur isolated without the development of nephropathy 
 The scenario of the link between the retinopathy and nephropathy in 
type 2 DM is not the same. Only about 56% of the diabetic nephropathy 
patients were complicated by retinopathy however none of the patients 
with non diabetic etiology as a cause for nephropathy had retinopathy41. 
Hence the presence of retinopathy has a 100% positive predictive value 
and a low negative predictive value. Treatment of nephropathy with the 
blockade of the angiotensin system has similar beneficial effects on the 
retinopathy42. 
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NON DIABETIC INVOLVEMENT OF KIDNEY IN 
DIABETIC INDIVIDUALS: 
It is essential to consider the presence of a non diabetic etiology in a 
diabetic individual in the following scenarios; 
1.! The presence of renal involvement without the presence of retinopathy in 
Type 1 DM and the occurrence of proteinuria usually within 5 years from 
the onset of diabetes in Type 1 DM. However, in Type 2 DM it is 
difficult to establish with certainty the onset of the diabetes and 
henceforth the time of proteinuria since the onset43.  
2.! The presence of a sediment cast in the urine microscopic examination. 
Though red cell cast can be present in severe diabetic nephropathy, its 
presence warrants the evaluation of non diabetic causes.45 
3.! The presence of other features in systemic examination that points 
towards secondary causes44.   
4.! The rapidity with which the renal function worsens. The diabetic 
involvement of the kidney usually progresses insidiously. Hence an acute 
or rapid decline in renal function in a diabetic patient; causes other than 
diabetic nephropathy should be ruled out.  
5.! The rapid decline in GFR of more than 30% from the baseline within a 
stipulated time period of 2 to 3 months following the administration of 
! 34!
ACE inhibitors also requires renovascular causes of declining renal 
function to be evaluated44. In such patients nephrosclerosis secondary to 
diabetes especially in older individuals must also be considered 
 
Hence the above mentioned patients should be evaluated with renal 
biopsy and other clinically warranted investigations. 
 
Fig 8. Flow diagram depicting evaluation of diabetic nephropathy 
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TREATMENT OF DIABETIC NEPHROPATHY: 
 The treatment of diabetic nephropathy involves a multidirectional 
approach 
 
GLYCEMIC CONTROL: 
 Achieving a good glycemic control prevents or retards the onset of 
development of diabetic nephropathy and reverses the biochemical and 
pathological changes in diabetic nephropathy. Pathological changes such 
as mesangial matrix expansion had experienced volume regression. 
Biochemical changes including proteinuria had decreased and even 
returned to normal46.  However, the biochemical improvement occurred 2 
years following a strict glycemic control47, 48 and the pathological 
improvement occurred 10 years following pancreatic transplantation in 
Type 1 DM49, 50 
 
DRUGS: 
ANGIOTENSIN INHIBTIORS:  
 The angiotensin inhibitors have produced dramatic effects in the 
treatment of diabetic nephropathy. The benefits demonstrated by the 
angiotensin inhibitors is beyond that could be explained by just reduction 
in blood pressure. The additional mechanism by which it improves renal 
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function is by its anti-proteinuric effect. The anti-proteinuric effect is 
produced by reducing the intraglomerular hypertension. The benefit 
derived from ACE inhibitors could also be explained by additional 
mechanisms which include interfering in the actions of transforming 
growth factoe!β.!The!use!of!ACE!inhibitors!has!the!maximum!benefit!
when!used!in!the!stage!of!moderately!increased!albuminuria!in!which!it!
can!revert!the!albuminuria!and!also!retard!the!progression!to!overt!
nephropathy51,!52.!When!used!in!patients!with!severely!increased!
albuminuria,!it!decreases!the!proteinuria!nad!retards!the!progression!of!
renal!loss53,!54.!!  
Though the benefit of ACE inhibitors has been markedly reduced in 
patients with advance kidney disease and ESRD, the rate of rise in 
creatinine may be reduced. 
 The benefit of ACE inhibitors is maximally studied in diabetic 
nephropathy due to Type 1 DM. Data on its efficacy in diabetic 
nephropathy due to Type 2 DM is limited. Although benefit similar to 
Type 1 DM is expected to be present 
 The beneficial effect on the use of Angiotensin receptor blockers 
and its renoprotective effect has been demonstrated in two trials55, 56. 
Decreasing the albuminuria using these drugs reduced the adverse 
cardiovascular events when such drugs were used in the first 6 months of 
diabetic nephropathy. Combination of ACE inhibitors and angiotensin 
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receptor blockers produced reduction in proteinuria that could be 
explained by the use of single drug alone as monotherapy57, 58. However, 
use of such combination is associated with increased adverse effects and 
increased hospitalization due to increased rate of acute kidney injury. 
Hence until further trials clearly demonstrating beneficial effects that 
outweigh the side effects are available, this combination is not 
recommended59. 
 
ALISKIREN AND ANGIOTENSIN INHIBITORS:  
 The combination of renin inhibitors with angiotensin inhibitors does 
not have anybeneficial effects. Rather it is associated with increased risk 
of adverse events as demonstrated in the ALTITUDE trial60. 
 
BARDOXOLONE METHYL: 
 Bardoxolone methyl is an antioxidant inflammatory molecule. 
Though the benefits of the drug has been explained in animal models of 
acute kidney injury, it is not recommended for use in diabetic 
nephropathy as suggested by data derived from BEAM trial61. 
 
PENTOXIFYLLINE:   
 Pentoxifylline is a non specific phosphodiesterase inhibitor and it 
has been used with success in the treatment of peripheral vascular disease 
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and in severe alcoholic hepatitis when the maddreys discriminant 
function scoring is more than 32. The additional benefit of using 
pentoxifylline in the treatment of alcoholic hepatitis over steroids was the 
renoprotective effect attributed to the pentoxifylline decreasing the 
incidence of renal failure. Similarly the effects of pentoxifylline was 
extrapolated for use in diabetic nephropathy and in a study, it was 
demonstrated that the drug either improves or stabilizes the GFR. 
However further studies are required to prove its efficacy before 
recommendation in the treatment of diabetic nephropathy62. 
 
CALCIUM CHANNEL BLOCKERS: 
 The use of non dihydropyridine calcium channel blockers in 
experimental models has shown that it decreases proteinuria. However, it 
was associated with increased degree of interstitial fibrosis and global 
sclerosis. The adverse effects observed with the non dihydropyrindine 
calcium channel blockers can be ameliorated by its combination with 
angiotensin inhibitors63. A similar effect on proteinuria was not 
associated with the use of dihydropyridine calcium channel blockers such 
as amlodipine. Rather, these drugs increase the rate of protein excretion. 
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ALDOSTERONE ANTAGONIST: 
 The use of aldosterone antagonist in patients on ACE inhibitors has 
an additive effect on decreasing proteinuria64,65. However, the use of this 
combination in clinical practice is associated with increased risk of 
hyperkalemia. Hence it is necessary to advice a strict and stringent 
potassium restriction in addition to salt and potassium restriction. 
 
PROTEIN RESTRICTION: 
 The reduction in intake of protein (and phosphorus) in diet to 
0.6g/kg/day markedly retards the rate at which GFR drops. In a study it 
was noted that protein restriction to 0.6 g/kg/day was found to have a 
75% improvement in the GFR decline66, 67. Further benefits of restricted 
diet such as decreased mortality and decreased onset of ESRD were noted 
in the low protein diet arm68. However, the exact mechanism remains 
unclear. 
 Protein restriction in these patients are also associated with increased 
of malnutrition due to associated restriction in the intake of carbohydrate 
and fat and due to augmented protein catabolism in diabetics attributed to 
insulin deficiency69. 
 It is well known data that proteinuria is a major factor that is 
responsible for progressive renal injury and advancement of CKD. This is 
attributed to the increasing interstitial fibrosis that is associated with 
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increasing degrees of proteinuria. A patient who has a 50% reduction in 
proteinuria in response to angiotensin inhibitors usually have a favorable 
prognosis. This was evident from IDNT and RENAAL trials. Increasing 
the reduction in proteinuria is associated with proportionate decrease in 
the loss of renal function70. 
 
SALT RESTRICTION: 
 Increasing intake of salt has been associated with decreased response 
of proteinuria to ACE inhibitors. Restriction of salt augments the 
response to ACE inhibitors by further decreasing proteinuria in patients 
with non diabetic kidney disease. Similar effect of augmented response to 
ACE inhibitors was also observed in diabetic nephropathy71, 72. Patients 
who fail to respond to respond to ACE inhibitors despite a drop in blood 
pressure may be poorly compliant with salt intake. 
 A daily salt intake of <70 meq/ day is associated with morbidity and 
mortality benefit. However this degree of salt restriction is not practically 
feasible. Hence a salt restriction of < 100 meq/ day is advisable.  
 
OTHER THERAPIES: 
 A reduction in weight by physical activity in patients with obesity 
and lowering the cholesterol levels in patients with hypercholesterolemia 
is associated with additional benefit in diabetic nephropathy. 
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 A multidirectional approach is hence required to treat patients with 
diabetic nephropathy.  
 
COMPLICATIONS OF CKD: 
 The complications of CKD include both acute and chronic: 
1.! Anemia and other hematological abnormalities 
2.! Acid- base disturbances including acidosis and hyperkalemia 
3.! Volume overloaded state  
4.! Renal Osteodystrophy 
5.! Dyslipidemias 
6.! Malnutrition  
7.! Acute on Chronic Kidney disease 
8.! Accelerated cardiovascular disease 
9.! Central and peripheral nervous system complications 
 
 
 Cardiovascular disease remains the most common cause of death 
in CKD patients. The incidence of cardiovascular complication in a CKD 
patient is 10 times more common than the general population73. The 
patient may reach advanced stages of cardiovascular disease even before 
the end stage renal disease is reached. The patient may not even reach the 
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ESRD stage due to cardiovascular death. The enhanced cardiovascular 
mortality is related to the increase in ischemic vascular disease and 
hypertension. The ischemic vascular disease is increased due to 
traditional risk factors such as diabetes mellitus, hypertension and 
hypercholesterolemia and also due to CKD related factors such as 
hyperparathyroidism, hyperphosphatemia and the inflammatory milieu 
attributed to CKD. These factors accelerate the atherosclerotic process 
leading on to increased incidences of heart failure and myocardial 
infarction74. The diagnosis of myocardial infarction is further complicated 
by the fact that troponin T levels may be elevated in CKD in the absence 
of myocardial ischemia. Hence it is required to document a rise in the 
troponin levels in patients suspected to have myocardial infarction. 
However, patients with elevated levels of troponin T levels without 
myocardial infarction are at increased risk of cardiovascular 
complications. The presence of hypertension in CKD is one of the most 
common complication. The salt and water retention, enhanced activity of 
the renin angiotensin axis are the major mechanisms for the development 
of hypertension which can be further augmented by the use of 
erythropoietic agents in CKD. In addition, renovascular disease may also 
contribute to the development of hypertension. Hypertension has 
implication in both cardiovascular system and in CKD. In cardiovascular 
system it causes left ventricular hypertrophy and heart failure. The left 
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ventricular dysfunction is both systolic and diastolic dysfunction. 
However, the presence of normal blood pressure or decreased blood 
pressure in advanced stages of CKD suggests poor left ventricular 
function. Ischemic factors combined with hypertensive remodeling in 
volume over loaded patient leads to failing heart and pulmonary edema. 
Failure can be augmented by the presence of anemia and AV fistula 
leading to high output heart failure. Sometimes, low pressure pulmonary 
edema can be due to uremia induced leaky pulmonary vasculature which 
is evidence by its improvement with hemodialysis.  
 The treatment of hypertension is very essential in retarding the 
progression of CKD and heart failure. However the target blood pressure 
remains controversial. The current consensus for target blood pressure 
includes 130/80 mmHg in CKD with proteinuria and 140/90 mmHg in 
CKD without proteinuria. ACE inhibitors and angiotensin receptor 
blockers play a major role and added benefit in also reducing the 
intraglomerular pressure and retarding the progression of CKD. Salt 
restriction, fluid restriction and use of a kaliuretic diuretic may be 
beneficial and usually multiple drugs will be required to achieve target 
blood pressure in patients with hypertension in CKD. However the use of 
ACE inhibitors should be cautious because of increased risk of 
hyperkalemia and acute on CKD may be precipitated in patients with 
renovascular disease. Potassium sparing diuretics should be used with 
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caution or avoided altogether in most patients. Lipid lowering 
medications in the presence of hypercholesterolemia though the data on 
use of statins in CKD is limited and benefits of statins in advanced CKD 
is less clear. Regular exercise and other addressing other modifiable risk 
factors are essential. The presence of pericariditis either symptomatic or 
asymptomatic is an indication for either intensification or commencement 
of renal replacement therapy. Heparin should not be used in hemodialysis 
for uremic pericarditis as it increases the chances of bleed into the 
pericardial fluid. Drainage of pericardial fluid should be considered in 
patients with recurrent pericardial effusion.  
 Anemia in CKD patients starts to develop in the third stage of 
CKD and becomes almost universal by the fourth stage. It is usually a 
normocytic normochromic anemia due to decreased production due to 
erythropoietin deficiency. Other factors contributing to the development 
of anemia in CKD includes deficiency of nutritional factors such as iron, 
folate and vitamin B12, bone marrow fibrosis due to 
hyperparathyroidism, bleeding diathesis, decreased red blood corpuscle 
survival, chronic inflammatory state, hemoglobinopathy and the presence 
of comorbid factors76. Clinical manifestations due to anemia include 
cardiovascular symptoms and when severe enough results in heart failure, 
poor cognitive function, impaired defense against host function, growth 
restriction in children. Poor response of anemia to erythropoietic 
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stimulating agents denotes poor prognosis. These patients are at increased 
risk of bleeding tendency due to decreased platelet aggregation, 
decreased consumption of prothrombin and impaired activity of platelet 
factor III. The CKD patients have greater risk for thromboembolism 
especially in patients with nephrotic range proteinuria due to loss of 
anticoagulants in urine. 
 The use of erythropoietic stimulating agents has revolutionized the 
treatment of anemia in CKD reducing the requirements of blood 
transfusion thereby reducing the complications associated with blood 
transfusion including transfusion associated infections, iron overload and 
increased increased sensitization to donor antigens increasing the risk of 
graft failure77. After ensuring adequate iron stores evidenced by serum 
ferritin, vitamin B12 and folate patients are treated with erythropoietic 
stimulating agents. If the patient is deficient in iron, IV iron is given to 
the patient to replace the iron stores. It is essential to note that these 
patients are at increased risk of bacterial infections. Anemia resistant to 
treatment with recommended doses of erythropoietic stimulating agents 
indicate either acute and chronic inflammation, inadequate dialysis, blood 
loss or hemolysis, severe hyperparathyroidism and presence of chronic 
infections. The use of erythropoietic stimulating agents have improved 
the hemoglobin but there was no improvement in the cardiovascular 
outcomes78. The use of these agents are associated with increased 
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thrombo embolic events and increased rate at which the patients progress 
to dialysis75. More studies are required for solving these issues. The target 
hemoglobin in CKD is 10 - 11.5 g/dl. The uremic platelet dysfunction is 
treated with desmopressin and optimal dialysis79. It is also worth noting 
that the favorable risk benefit profile applicable in the general population 
do not apply to the CKD population due to altered balance between the 
procoagulant and anticoagulant factors. And when required it is prudent 
to use unfractionated heparin than to use low molecular weight heparin. 
The newer oral anticoagulants have to be assessed for dosage as per the 
eGFR. 
 The fluid and electrolyte disturbances in CKD alters the internal 
milieu resulting in various complications. There is retention of salt and 
water resulting in volume overloaded state. This is especially the case 
when the dietary sodium exceeds the ability of the kidney to clear 
sodium. And as long as the kidney eliminates free water that the patient 
consumes there is no hyponatremia. Hence hyponatremia is less common 
in CKD and responds to fluid restriction. The volume overloaded state 
can be treated using diuretics including metalazone and loop diuretics. 
The state of resistance to loop diuretics in CKD suggests that higher 
doses of loop diuretics may be required. Fluid restriction is advisable 
only when there is hyponatremia. Volume overloaded state not 
responding to diuretics is an indication for renal replacement therapy. 
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Further in these patients there is impairment in the ability of the tubules 
to reabsorb sodium and hence in volume depleted states such as GI loss 
and overzealous use of diuretics the contracted plasma volume can impair 
renal function. The proper fluid therapy in such cases can restore the 
renal function. 
 The hyperkalemia in CKD occurs with advanced stages of CKD 
especially when associated with high potassium diet, acidosis, catabolic 
state, use of potassium sparing diuretics, angiotensin inhibitors, 
hemolysis, blood transfusion. However, in patients with diabetes, sickle 
cell disease, obstructive uropathy hyperkalemia can occur at an earlier 
stage due to hyporeninemic hypoaldosteronism. Hyperkalemia is 
managed by dietary restriction of potassium and use of diuretics that 
favors potassium excretion and sodium polystyrene that sequesters GI 
potassium and favors GI loss.  
 The acidosis in initial stages of CKD is characterized by normal 
anion gap. It is due to impaired hydrogen ion excretion, not due to 
impaired acidification, but due to impaired ammonia production which is 
further depressed by the presence of hyperkalemia. The advanced stages 
of CKD is characterized by high anion gap. The bicarbonate level less 
than 20 – 23 mmol/L is associated with increased rate of catabolism in 
the body. This is prevented by sodium bicarbonate supplementation 
which retards the progression of CKD.         
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 The disorders of calcium and phosphate metabolism affects the 
bone vascular bed and soft tissues. In advanced CKD as the eGFR drops 
to <60 ml/min/1.73m2, the phosphate level in the blood increases leading 
to increased levels of FGF – 23. It results in decreased calcitriol and 
hence decreased serum calcium levels which results in elevated 
parathormone levels. The spectrum of bone disorder ranges from high 
turnover to low turn over bone disease80. The result of elevated 
parathormone in an untreated patient results in high turn over from the 
bone resulting in osteitis fibroa cystica resulting in the formation of bone 
cyst which may become hemorrhagic leading to the name brown tumor. It 
may also lead to bone marrow fibrosis. However, treating the patient with 
calcium based phosphate binders such as calcium carbonate and calcium 
acetate results in hypercalcemia and decreased parathormone levels and 
hence the increased calcium gets deposited in the vascular bed and soft 
tissues81. Decreased mineralization of the bone results in adynamic bone 
disease resulting in fractures82. Hence the use of non calcium based 
phosphate binders including sevalamer and lanthanum avoids the 
complication of adynamic bone disease and soft tissue calcification, The 
use of calcitriol may be given to increase the calcium levels which results 
in suppression of parathormone. These patients needs to be monitored for 
hyperphophatemia. Hyperphosphatemia can be manages using phosphate 
restricted diet and phosphate binders. FGF 23 levels in these patients also 
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increase cardiomuscular morbidity because it can cause cardiac fibrosis. 
Calciphylaxis is a dreaded complication in advanced stages of CKD. It 
results in ischemic necrosis of the skin which is preceded by livedo 
reticularis. It occurs in patients with severe hyperparathyroidism, use of 
oral calcium based phosphate binders and use of warfarin. Hence when it 
occurs warfarin if used should be switched to other drugs. 
 Other complications in CKD include peripheral neuropathy which 
is initially sensory and subsequently progresses to motor involvement can 
occur. Other neuromuscular abnormalities may also occur83. The use of 
renal replacement therapy may reverse the neuropathy especially when 
done before motor component occurs. Gastrointestinal abnormalities due 
to CKD results in uremic gastritis which may result in vomiting, 
abdominal pain84. The patient may also have dysgeusia. Malnutrition is 
common in CKD attributed due to poor absorption by the uremic gut and 
due to increased protein catabolism in these patients. In women, estrogen 
level decreases, causes menstrual abnormalities, infertility and increased 
rates of spontaneous abortion. Only 20% of patients with advanced CKD 
give rise to live births. In males it results in sexual dysfunction and 
oligospermia. Dermatologic abnormalities include pruritus in uremic 
patients and when gadolinium contrast is administered in CKD patients it 
may result in nephrogenic fibrosing dermopathy which is highly fatal85.                      
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CKD IN THE ELDERLY POPULATION 
 
 The CKD in the elderly has wide spread implications. Firstly, the 
geriatric population in the developed and the developing middle and low 
income countries has increased due to decreased deaths owing to the 
advances in the field of therapeutics. As a result, old age population 
contribute to a significant proportion of CKD in the general population. 
This is evident from the increase in prevalence of CKD from 37% to 47% 
in the aged population >70 years’ age86. 
 With the introduction of definition by the National Kidney 
Foundation – Kidney Disease Outcome: Qualitative initiative in 2002, 
there was a paradigm shift in the perspective and approach to CKD. 
Individuals at risk of ESRD were identified much earlier and preventive 
measures were taken to retard the progression of CKD. However, in the 
process large proportion of old age individuals were detected as CKD. 
This created two different perspectives. First perspective was, this 
definition has brought out the epidemic of CKD which was under 
reported. The individuals who were identified by the process were at 
increased risk of adverse cardiovascular events and physical functioning 
which could be addressed to improve morbidity and mortality. The 
second perspective is, the definition without intending to has over 
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diagnosed CKD. This resulted from failure to differentiate between 
chronic kidney disease and the senescence of normal kidneys. Also the 
use of formulas in the elderly population has been less validated and 
hence more patients without CKD may be diagnosed with the disease. 
 
ESTIMATION OF GFR – FALLACIES IN OLD AGE: 
 The estimation of GFR came into vogue due to the cumbersome 
procedure of collecting 24 hour urinary sample for calculation of 
creatinine clearance to calculate GFR. Initially estimation of GFR was 
done using Cockroft Gault formula. Subsequently the formula introduced 
by the Modification of Diet in Renal Diseases (MDRD) study provided 
better results in estimating eGFR than cockroft gault formula. However 
the eGFR estimated by the MDRD formula correlated better in the lower 
range of GFR but not so in the higher ranges. Hence the CKD – EPI 
formula was subsequently used which has better correlation with GFR 
than the MDRD formula. The advantage of CKD-EPI formula was that it 
did not over estimate the number of patients having CKD. However it did 
not hold good in the elderly population in whom it over estimated the 
prevalence of CKD87. 
 Hence the shift in marker from the use of creatinine in estimating 
GFR to using cystatin C. The formula containing estimation of GFR 
using both cystatin C and creatinine is considered best. The use of 
! 52!
cystatin C has the following advantages. Cystatin C sources from 
nucleated cells. It is filtered across the glomerulus reabsorbed in the 
proximal tubules and is broken down. Cystatin C is not dependent on 
muscle mass. It is less affected by gender, race and age. It correlates 
better and linearly with cardiovascular adverse outcomes than creatinine. 
Hence forth, estimation of GFR using formulas derived from cystatin C 
and creatinine has the best prediction. It is limited by its availability 
though it is expected to increase in availability88. 
 Hence it is recommended by the KDIGO that when a patient is 
diagnosed as CKD due to GFR < 60 ml/min/ 1.73 m2 with no other 
markers of renal damage and has been classified as Stage 3A according to 
the GFR, it is essential that the GFR be estimated by using formulas 
using creatinine and cystatin C. If the calculated GFR is >60 ml/min/1.73 
m2, then the patient does not have CKD. In this manner it was found that 
a large number of older individuals were reclassified from the Stage 3A 
to having no CKD. 
 
THE PROGRESSION OF CKD VERSUS RENAL SENESCENCE: 
 The glomerular filtration rate rises to maximum during life at 4th 
decade and subsequently it starts to drop after at a rate of 8 
ml/min/1.73m2. It is to be considered that the decline in GFR is an ageing 
process and should not be confused with CKD. Baltimore longitudinal 
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study included patients for monitoring the creatinine clearance for 
estimating GFR89. The included patients did not have any comorbidities, 
renal disease or drug intake that could interfere with GFR and its 
estimation. It was found that the GFR progressively decreased with age. 
However it was the average GFR of the study population that decreased, 
though a subset of patient population did not have a decline on GFR 
suggesting an inter individual variation in GFR decline89, 90.  
 
RISK FACTORS IN CKD PROGRESSION: 
 Compared to the younger individuals, the risk factors of diabetes 
mellitus, systemic hypertension plays a major role in etiology and 
progression of CKD. Sufficient time would have lapsed following the 
onset of diabetes mellitus, systemic hypertension which are the main 
determinants in the progression of CKD. Other risk factors such as 
renovascular disease, obesity, hypercholesterolemia may also play a role 
in this population. Smoking, family history and cardiovascular diseases 
also plays role. 
 
HYPERTENSION: 
 Systolic component of blood pressure is a major determinant in the 
progressin of CKD and correlated with it linearly. However the target 
blood pressure in the treatment of CKD patients has been controversial. 
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The recommendation by the Joint National Committee 8 in individuals 
aged more than 60 years of age is 150 / 90 mmHg of blood pressure. 
However, it has been documented that in patients with proteinuria, a 
lower target for systolic blood pressure retards the progression of blood 
pressure.  Hence KDIGO recommends that blood pressure target in 
patients without proteinuria is 140/90 mmHg. The blood pressure target 
in patients with proteinuria (albuminuria >30 mg/dl) is 130/80 
mmHg.However it is also to be noted that older individuals are more 
prone for side effects such as postural hyotensionwith the use of 
antihypertensives. 
 ACE inhibitors / ARBS are preferred as antihypertensive in 
individuals with proteinuria due to anti-proteinuric effect. However the 
safety data regarding the side effect profile of ACE inhibitors and ARBS 
are limited in the elderly population and is controversial. In RENAAL 
study it has been shown there was no increased incidence of 
hyperkalemia in older patients and it prevented the progression to ESRD 
in 50% patients91. However, in a study, use of Lisinopril in an older 
indivuals with an eGFR of <60 ml/min/1.73m2 was associated with an 
increased incidence of hyperkalemia92. In AASK trial, the occurrence of 
hyperkalemia was more common in the ageing population. Hence, 
KDIGO recommends that ACE inhibitors / ARBs be used in diabetic 
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patients with albuminuria >30 g/day and in non diabetic patients with 
albuminuris >300 g/ day 
 
DIABETES: 
 Diabetes is a major contributor to CKD in the elderly. The 
correlation between glycemic control and renal complications were 
evaluated and it was found that tight glycemic control was decrease in the 
degree of albuminuria. However, it was not clear if it retarded the 
progression in CKD. And it was further associated with increased 
incidence of hypoglycemia, weight gain, arrhythmias and increased 
morbidity in the tight control arm. The risk of hypoglycemia was more in 
the diabetic CKD which was more in diabetic patients without CKD 
which was in turn more than non diabetic CKD. Hence KDIGO 
recommends a target HbA1C of <7% and it should be higher than 7% for 
fear of complications in individuals with HbA1C >7%. 
 
ACUTE KIDNEY INJURY: 
 AKI is considered as risk for development of CKD and its 
progression, especially in older individuals because of poor renal reserve 
in this population. Hence a sudden drop in functioning glomerular tissue 
would increase the delivery of blood to other functioning glomerulus 
which would increase the intraglomerular hypertension further worsening 
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the functional status of the kidney. Further, CKD patients are at more risk 
of developing acute worsening of renal function. NSAIDs is a common 
cause and hence should be avoided in patients with CKD. Also many 
drugs having renal excretion and older patients on multiple drugs, it is 
essential to consider drug to drug interaction and appropriate dosing of 
drugs in this patient population and hence at increased risk of medicine 
related complications. 
 
NON RENAL COMPLICATIONS IN AGEING 
KIDNEY: 
CARDIOVASCULAR OUTCOME: 
 CKD patients are at three times higher risk of developing adverse 
cardiovascular events and cerebrovascular accidents. This is especially 
prevalent in the patients with CKD stage 3 or higher. As suggested by the 
cardiovascular health study index, participants with CKD and 
microalbuminria had 2.5 times higher risk of myocardial infarction93.  
 Patients with age >65 years, even mildly increased serum 
creatinine was associated with increased cardiovascular mortality as 
compared with individuals with normal serum creatinine94. Statins use 
decrease adverse cardiovascular events in CKD patients. However, this 
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effect has been documented only on patients who are not on hemodialysis 
and not inpatients who are on hemodialysis. 
 
COGNITIVE IMPAIRMENT & PHYSICAL FUNCTIONING:  
 Cognitive dysfunction is increased in elderly patients with CKD. 
ESRD and increasing age are independent risk factors for cognitive 
dysfunction. The areas affected in cognitive testing include attention and 
executive function95. CKD in elderly increases the risk of frailty. Frailty 
increases disability. Disability increases admissions to nursing old age 
homes. CKD patients can have low levels of physical activity. 
 
BONE DISEASE:  
 The metabolic bone disease results due to milieu changes 
secondary to CKD. Early CKD is associated with increase in FGF 23 and 
decreased 1,25 dihydroxy vitamin D3. As CKD progresses parathormone  
and phosphorus levels increase in advance stages of CKD. The 
predominant skeletal finding in CKD patients are osteoporosis. However 
it has not been found that CKD decreased bone mineral density. However 
it predicts that the bone loss is increased, If the bone mineral density is 
low, the rate of fracture is increased in both dialyzing and non dialyzing 
CKD. The drugs for osteoporosis can be prescribed if eGFR <30 
ml/min/1.73m2.  
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PROGNOSIS IN OLD AGE: 
 Although the prevalence of CKD is increased in older age, it is not 
associated with increased progression to ESRD. This is attributed to early 
death due to other complications of CKD in the elderly population and 
due to over diagnosis of CKD. For any given GFR the elderly patients are 
at more risk of dying than the young individuals96. 
 
REFERRAL TO A NEPHROLOGIST:  
 It is necessary to consider referral to a nephrologist in the following 
scenarios: 
1.! Nephrotic syndrome 
2.! Proteinuria which is less than 1 g in a non diabetic kidney disease 
3.! Non urologic hematuria 
4.! Recurrent hyperkalemia 
5.! Rapid decline in eGFR >5ml/min/year. 
6.! eGFR <30 ml/min/1.73m2 
It is recognized that CKD in elderly population is progressively 
increasing and lack of adequate studies in this population cohort leads to 
scarcity of data. Hence adequate studies and trials are required addressing 
CKD in the elderly.  
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The study was conducted in Institute of Internal Medicine, Rajiv Gandhi 
Government General Hospital, Chennai - 600003 between April 2015 and 
September 2015. Patients presenting to the Emergency department in 
Institute of Internal Medicine and Nephrology Ward were considered for 
the study. Rajiv Gandhi Government General Hospital is a tertiary care 
referral center in Chennai catering to the referral services from hospitals 
across Tamil Nadu. Hence the subjects in the study represented various 
population from across Tamil Nadu 
 
NUMBER OF SUBJECTS: 
100 
 
INCLUSION CRITERIA: 
1.! Patients with Chronic Kidney Disease as defined by National 
Kidney Foundation (NKF) Kidney Disease: Improving Global 
Outcome (KDIGO) 2012 clinical practice guidelines 
2.! Patients with Age > 60 years 
 
EXCLSUION CRITERIA 
1.! Patients with Chronic Kidney disease aged less than 60 years 
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 Patients presenting to the emergency department in the institute of 
internal medicine serially and patients admitted in the nephrology ward 
were subjected to the history and physical examination according to the 
questionnaire and the investigations done were recorded in the proforma 
The following parameters were assessed 
1.! History was obtained according to the proforma. History of 
diabetes mellitus, systemic hypertension, smoking, alcohol 
consumption, other substance abuse, duration of CKD were noted 
down 
2.! The body mass index, vital signs of the patient, ambulant status of the 
patient, systemic findings, cognitive dysfunction as assessed by 
MMSE and mini cog test, fundus examination to look for diabetic 
retinopathy and hypertensive retinopathy, clinical hearing 
assessment, presence of joint disease were assessed. 
3.! The frequency of malnutrition as the stage of CKD progressed and 
the average of Body mass index across different stages of CKD were 
analyzed. 
4.! The presence of other geriatric complications including frailty as 
assessed by osteoporotic fracture index, falls risk assessment, urinary 
incontinence was also assessed 
5.! The investigations including hemoglobin, mean corpuscular volume, 
liver function test, Urine routine, renal function testing including the 
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presenting creatinine and creatinine from the previous medical 
records, serum sodium, serum potassium, arterial pH, pCO2, 
bicarbonate, Anion gap and special investigation if any done were 
noted down.  
6.! The hemoglobin distribution and the prevalence of anemia in 
different stages of CKD, the type of anemia (microcytic, normocytic) 
were assessed in the study population. 
7.! The distribution of serum sodium and potassium in different stages of 
CKD and the prevalence of hyponatremia and hyperkalemia in 
different stage CKD were analysed. Comparison of potassium level 
between diabetics and non diabetics were also assessed. 
8.! The distribution of the arterial pH and arterial bicarbonate in different 
stages were assessed. 
9.! The eGFR was calculated using the variables required using cockloft 
gault formula, MDRD formula and CKD - EPI formula. 
10.!The ultrasonography and the ejection fraction if clinically warranted 
were done and noted. The mean distribution of the ejection fraction in 
the subjects assessed were analyzed. The distribution of mild, 
moderate and severe Left ventricular systolic function as assessed by 
echocardiography were analyzed. 
11.!The complications including Acute on chronic kidney disease, Acute 
pulmonary edema, acidosis, hyperkalemia, encephalopathy, 
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pericarditis were recorded and assessed for correlation with the 
progression in the stage of CKD 
12.!Viral Markers including HbsAg, antiHCV, HIV were recorded 
13.!The Renal replacement therapy if initiated including mode, centre, 
funding for renal replacement therapy were recorded 
14.!The probable etiology of the CKD were ascertained and their 
distribution frequency in the study population were analyzed 
15.!The patient were followed up either by contacting through telephone 
or during their review visit. If the patient is not on follow up the 
reason for not being in follow up were noted down. 
16.!The analysis of statistical significance were carried out using SPSS 
software version 20.0 
 
CONSENT: 
 
Written and informed consent were obtained from all the participants in 
feasible cases or their attenders 
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 The results were tabulated and analyzed. The demographic 
distribution, clinical profile, complications, the distribution of 
complications across the stages of CKD according to the eGFR as 
estimated by CKD - EPI formula, etiology and follow up of the patients 
were tabulated and analyzed.  
 
 The subjects included in the study were more than 60 years. The 
minimum age of the subject was 60 years and the maximum age of the 
study population was 80 years. The mean age of the population studied 
was 65.2 years with a standard deviation of 5.1. The distribution of the 
curve is depicted as follows 
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 The study population included 46 males and 54 female. 
 
 
 
 
The study population consisted of 61 patients with diabetes mellitus 
amounting to 61% of the study population and 75 subjects with systemic 
hypertension amounting to 76 percent of the study population. 38 patients 
with Diabetes mellitus had non proliferative diabetic retinopathy and 1 
patient had proliferative diabetic retinopathy. 17 patients with 
hypertension had hypertensive retinopathy. 
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25 subjects among males consume alcohol accounting for 54.3% of 
the male population and 1 subject among the female population consume 
alcohol accounting for 1.8% of the female population 
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20 patients among males smoke cigarettes accounting for 43.5% of the 
male population and 1 patient among females smoke accounting for 1.8% 
of female population. 
 The study population had the duration of CKD distributed over a 
range from minimum 3 months to a maximum of 14 years. The mean of 
the duration of CKD was 1.49 with a standard deviation of 1.9. The 
distribution curve of the duration of CKD of the study population is as 
shown below. 
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 The presentation serum creatinine of the study subjects were 
documented and the eGFR was calculated as per the CKD - EPI equation. 
The mean presenting creatinine of the population was 4.5 mg/dl with a 
standard deviation of 4.0 mg/dl. 
 The study population were categorized according to the stage of 
CKD and the distribution of the subjects across various stages of CKD 
were analyzed. The patients presented in various stages of CKD ranging 
from IIIa, IIIb, IV and V. The frequency of the study population across 
various groups is depicted as follows 
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The analysis of the prevalence of the complications such as cognitive 
dysfunction, frailty, urinary incontinence, falls risk and ambulant state of 
the patients in the geriatric population were assessed. 
 The cognitive dysfunction as assessed by Mini-mental state 
examination concluded that 17 patients had cognitive dysfunction and 65 
patients did not have cognitive dysfunction. The cognitive dysfunction as 
assessed by Mini-cog test concluded that 15 patients had cognitive 
dysfunction and 67 patients did not have cognitive dysfunction. 18 
subjects could not be assessed for cognitive dysfunction using either 
MMSE or Mini-Cog test because of the presence of encephalopathy. 
Though the cognitive dysfunction as assessed by MMSE estimated 2 
patients to have cognitive dysfunction in addition to that estimated by 
mini cog test, it was not statistically significant. 
 In the patient population studied, 13% had urinary incontinence, 
17% were underweight and malnourished. 60% of the patient population 
were ambulant at presentation. 40% of study population were either bed 
ridden or required support for mobility. 
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In the study population 65% of the patients had low risk for fall, 
however 4% and 31% had moderate and high risk for fall respectively. 
 
 
 In the study population, 45% of the patients had degenerative joint 
disease involving the knee joint, hip joint or shoulder joint as evidenced 
by clinical examination or radiological imaging. 2% of the patients had 
fractures involving the neck of femur due to a fall. 53% of the population 
did not have any joint involvement.  The Frailty assessment by 
Osteoporotic fracture index revealed than 76% of the study population 
was frail, 6% pre-frail and 18% without any frailty. 
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 Though the absolute number of subjects involved by malnutrition 
and cognitive dysfunction is more in advanced stages of CKD, the 
percentage of the corresponding population being involved is not 
statistically significant. However, the quantitative analysis of the Body 
Mass Index across the stages of CKD had shown the mean of BMI in 
stages IIIa, IIIb, IV, V were 23.58, 23.24, 21.17, 21.16. The difference in 
BMI between the stages were statistically significant.  
 
 
 
 
 
 
 
! 79!
 
 
 
 
! 80!
The frequency of various complications such as Acute on chronic 
kidney disease, acute pulmonary edema, acidosis, pericarditis and other 
complications were analysed and compared with different stages of CKD. 
The increased frequency of complications such as acute on chronic 
kidney disease and acidosis as the stage of CKD progressed were 
statistically significant. Though the absolute number of patients involved 
had increased as the stage of CKD progressed, it was not statistically 
significant with respect to acute pulmonary edema, encephalopathy and 
other complications. The other complications that had occurred in the 
study population includes 4 patients with hypokalemia, 2 patients with 
cerebrovascular accident and 1 patient with hypoglycemic episode. None 
of the patients had complications of pericarditis. 
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 However quantitative analysis of the mean of the arterial pH across 
various stages of CKD has shown a statistically significant difference in 
pH between groups. The quantitative analysis of the mean of the 
bicarbonate levels in various stages of CKD has shown a statistical 
significant difference  
 The mean sodium level between different stages of CKD were not 
statistically significant. Neither was the prevalence of hyponatremia 
statistically significant between different stages of CKD. The quantitative 
analysis of the mean of potassium levels has shown statistically 
significant difference between different stages of CKD. And the 
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frequency of hyperkalemia has shown statistically significant difference 
between different stages of CKD. 
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There was  no statistically significant difference in the frequency of 
hyperkalemia between diabetics and non diabetics. Neither was there any 
statistically significant difference in the mean of potassium between the 2 
groups. 
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The mean distribution of hemoglobin in the study population was 
9.2 g/dl with a standard deviation of 2.2. The normal distribution curve of 
the population is as shown below 
 
 
The prevalence of anemia in the study population was 91% with 93% of 
males 89% of females were affected. 70% of the patients had normocytic 
anemia and 30% of the patients had microcytic anemia. 
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The comparison of the mean of hemoglobin between the stages of CKD 
showed a statistical significance between the groups. 
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 The distribution of the liver enzymes including SGOT, SGPT and 
alkaline phosphatase were analyzed. The mean of SGOT was 24.5 with a 
standard distribution of 18.3. The mean of SGPT was 24.1 with a 
standard deviation of 17.5. The mean of alkaline phosphatase was 107.5 
with a standard distribution of 68.4 
 
 
 
 
 
 
 
! 91!
 
 
 
 The Left ventricular ejection fraction was estimated in 54 subjects. 
The distribution curve of the ejection fraction of the study population is 
as shown below with a mean of 53.5 with a standard deviation of 11.0. 
The frequency of ejection fraction  
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The prevalence of Left ventricular systolic dysfunction in the subjects 
who were assessed were 53.7%. The frequency of patients with mild, 
moderate and severe Left ventricular systolic dysfunction were 21, 4 and 
4 respectively. 
 
 
 
 
Analysis of the patients on renal replacement therapy revealed that 
a total of 25% of the study population were on renal replacement therapy. 
2% of the population were already on hemodialysis, 3% of the population 
were on peritoneal dialysis and converted to hemodialysis and 20% of the 
patients had been initiated on peritoneal dialysis. None of the patients 
were initiated for renal transplantation. 
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 The contribution of the various etiology and contributory factors in 
the development of chronic kidney disease in the study population were 
analyzed. The frequency of Diabetes Mellitus, Systemic hypertension, 
Chronic glomerulonephritis, Chronic interstitial nephritis, Ischemic 
nephropathy, Autosomal dominant polycystic kidney disease, myeloma 
kidney was 61, 75, 19, 8, 3, 2, 1 respectively. However, the cause could 
not be ascertained in 4 of the patients.  
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 Subsequent follow up of the patient were analysed based on if they 
are residing in urban area or rural area. In the study population, 57% of 
the patients were from urban area and 43% of the patients were from rural 
area. 22 patients from the urban population (38.6%) and 17 patients from 
the rural population (39.5%) could not be contacted. The loss of contact 
was either dus to loss of communication or due to death of the subject.  
 Among the patients who had been contacted, 6 patients from the 
urban population (17.14%) and 15 patients from the rural population 
(57.6%) did not follow up for medical consultation. This difference 
between the rural and the urban population was statistically significant. 
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DISCUSSION 
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 The above analysis of etiology, clinical and lab profile and the 
outcome of the patient with chronic kidney disease has wreathed into the 
wider aspects of chronic kidney disease in geriatric population. The 
above analysis addresses both the complications of CKD and the 
complications pertaining to geriatric population. This analysis 
encompassing wider aspects of the chronic kidney disease in geriatric 
population arose to the need created by the definition of CKD as defined 
by the NKF KDOQI that was introduced in the year 2002. In doing so, 
there was a paradigm shift in the perspective of chronic kidney disease. It 
transformed from treating end stage renal disease to preventing and 
retarding the progression of CKD. But in doing so larger proportion of 
older individuals were addressed under the label, increasing the incidence 
and prevalence of chronic kidney disease in geriatric population101. This 
further is augmented by the rising geriatric population in the developing 
low and middle income countries which has resulted from the betterment 
of life expectancy97. It was also noted that it was this geriatric population 
that was at increased risk of complications from chronic kidney disease98 
and the complication in geriatric population such as cognitive 
dysfunction, falls and falls risk, frailty99, urinary incontinence was 
increased in the geriatric population with CKD than the general geriatric 
population100. 
 The study population had a mean age of 65.2 years with a female 
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preponderance. The age ranged from a minimum of 60 years to a 
maximum of 80 years. 54.3% of the male population and 1.8% of the 
female population consumed alcohol whereas 43.5% of the male 
population and 1.8% of the female population had history of smoking. 
None the subjects involved had any history of any other substance abuse. 
The study population consisted of 61 diabetics and 75 hypertensive 
patients. The prevalence of diabetic retinopathy was 64% with non 
proliferative diabetic retinopathy accounting for 62%. This high 
incidence is explained by the increased association of diabetic retinopathy 
with overt nephropathy. This finding was similar to the incidence noted 
by Parvin et al, 1992102. Further there was decreased finding of 
proliferative retinopathy as opposed to the study reported by Penno et al, 
2012103 in which proliferative retinopathy was reported in 15.28% of the 
patients with CKD. This low composition of proliferative diabetic 
retinopathy can be accounted by the predominant asymptomatic nature of 
the non proliferative diabetic retinopathy and symptomatic nature of 
advanced diabetic retinopathy. Hence does not reflect the community 
prevalence of proliferative and non proliferative retinopathy. The 
prevalence of hypertensive retinopathy which included Grade 1 and 
Grade 2 retinopathy accounted for 23% of the patients with hypertension. 
This is in concordance with the prevalence of retinopathy detected in 
hypertensive population by Shantha et al, 2010104.  
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 The study population had predominant patients distributed among 
the stages of CKD IV and V which accounted 79% of the population. The 
study population was homogenous in having an overt nephropathy with 
an estimated GFR of <60 ml/min/1.73m2. The cognitive function assessed 
by MMSE had shown 17 patients to be affected by dysfunction whereas 
mini cog test had shown 15 to be involved. This difference was not 
statistically significant. However, assessing cognitive dysfunction in 
various stages of CKD did not show a statistically significant increase 
with the progression of CKD. In the higher stages of CKD, the 
assessment was confounded by the presence of encephalopathy in whom 
it could not be assessed. Urinary incontinence was present in 13% of the 
population. 40% of the study population was non ambulant requiring 
support for carrying out activities. This non ambulant state was attributed 
to fracture, severe degenerative joint disease, frailty, malnutrition, 
presence of encephalopathy, anemia, left ventricular dysfunction and 
cerebrovascular accident in the study population. Assessment of falls risk 
revealed 38% and 5% of the patients had severe and moderate risk of 
falls. These patients were initiated on prevention of falls algorithms 
advised by the clinical practice guidelines from the American geriatric 
society. The factors responsible for the high risk state were analyzed, 
addressed and referred to a specialist appropriately when required. 
Assessment of the population for frailty revealed 76% and 6% of the 
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population to be frail and pre-frail respectively. 2% of the patients had 
fracture neck of femur which had occurred after the onset and diagnosis 
of CKD and 45% of the patients had degenerative joint disease involving 
the knee, hip and shoulder joints. The degenerative joint disease and 
frailty had also contributed to the non ambulant state of the patient. 17% 
of the patients had underweight as diagnosed using Body mass index for 
Asian standards (<18.5). The increase in underweight as the stage of 
CKD progressed was not statistically significant. However, there was a 
progressive drop in BMI as the stage of CKD progressed. This 
progressive decrease in BMI with advancing stage of CKD could be 
attributed to uremic gastritis, catabolism aggravated by uremic state, 
inflammatory state, progressive decrease in hemoglobin, urinary protein 
loss, presence of comorbidities such as diabetes and advanced heart 
failure105 
  The frequency complications of CKD such as acute on CKD 
increased as the stage of CKD increased which was statistically 
significant. However, the increase in complications such as acute 
pulmonary edema, encephalopathy and other complications as the stage 
of CKD progressed was not statistically significant. None of the patients 
had clinical, ECG or Echo evidence of pericarditis emphasizing the rarity 
of the complication in the modern era and that it is more often observed 
in patients who are poorly dialyzed or poorly adherent to the schedule 
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rather than in those starting dialysis. 
 The analysis in acid base balance revealed increased incidence of 
acidosis as the stage of CKD progressed which was also evident from the 
progressive decrease in pH as the eGFR declined. The bicarbonate levels 
also decreased substantially as the eGFR declined. The acidosis is due to 
retention of hydrogen ions, organic acids and increased excretion of 
bicarbonate. The prevalence of hyponatremia and the levels of sodium 
did not vary as the CKD progressed. The prevalence of hyperkalemia 
progressively increased and the levels of potassium level progressively 
increased with increasing stages of CKD. The hyperkalemia in the study 
population in advanced stages could be attributed to the progressive 
increase in acidosis as evidenced by decreasing pH and decreasing 
bicarbonate, anemia for which blood was transfused, diet high in 
potassium, acute on chronic kidney disease, diabetes and drugs including 
potassium sparing diuretics prescribed for cardiovascular disease and 
ACE inhibitors. However, there was no difference in the prevalence of 
hyperkalemia and the potassium levels in the serum between diabetic and 
non diabetic patients. This expected observation occurs due to the added 
factor of hyporeninemic hypoaldosteronism. The lack of this difference 
could be explained by the fact that such differences will be exaggerated 
and obvious in the early stages of CKD 1 and 2 where the contribution of 
CKD in the development of hyperkalemia would be limited107.  
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 The mean hemoglobin concentration of 9.2 g/dl. The prevalence of 
anemia in the study population was almost pervasive involving 93% 
males and 89% females.  The anemia was normocytic in 67% of the 
population and microcytic in 33% of the population. The mean 
hemoglobin concentration had progressively decreased with advancing 
CKD which was statistically significant.   
 The mean aspartate transaminase and alanine transaminase levels 
24.5 and 24.1. However, the expected observation of decreased AST and 
ALT were not observed due to the presence of confounding factors that 
could cause the elevation of liver enzymes. These include diabetes 
mellitus and hypercholesterolemia leading to occurrence of Non alcoholic 
fatty liver disease which were subclinical , drugs including statins and 
sepsis leading on to organ dysfunction. The mean alkaline phosphatase 
level was 107.5 
 The mean of ejection fraction of the left ventricle was 53.5%. 39%, 
7% and 7% had mild, moderate and severe left ventricular dysfunction. 
However, the difference in systolic dysfunction between groups did not 
reach statistical significance due to insufficient data on ejection fraction 
in the study population.  
 Further in the study population 2 patients were already on 
hemodialysis initiates at a private center with private funding. The 
vascular access had been established in the IJV for both the patients. 2 
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patients had been started on PD and later converted to HD, 20% of the 
patients were already on or were started on peritoneal dialysis. The 
funding for the dialysis were institutional. 
 The distribution of the etiology and contributory factors include 61% 
patients with diabetes mellitus, 75% patients with hypertension, 19% 
patients with chronic glomerulonephritis, 8% patients with chronic 
interstitial nephritis, 3 patients with items nephropathy, 2 patients with 
autosomal dominant polycystic kidney disease, 1 patient with myeloma 
kidney and the cause could not be ascertained in 4% of the population. 
 Subsequent follow up of the patients had shown that 38.6% of the 
urban population and 39.5% could not be contacted either due to loss of 
communication or the death of the patient. 17.14% from the urban 
population and 57.6% in the rural population did not follow up for 
medical consultation. This difference between the rural and urban 
population in follow up was statistically significant. The reasons cited by 
the patients and / or their relatives for not following up in the consultation 
services were due to indirect expenses incurred by the patient due to stay 
and travel and social stigma of the geriatric population. However, such 
decrease in follow up in rural population could be further attenuated by 
extending nephrology consultation services across the state. 
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CONCLUSION 
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 The analysis of the CKD patients has shown that Diabetes mellitus 
and systemic hypertension are the most common etiology and 
contributory factor affecting three – fourths of the study population. The 
various complications of the geriatric population including frailty, 
cognitive dysfunction and fall risk were higher in CKD patients as 
compared to the risk at the general population level. The complications 
pertaining to CKD such as malnutrition, hemoglobin, acidosis, 
hyperkalemia and acute on CKD had shown progressive worsening and 
increased incidence with the advancing stages of CKD. However, the 
prevalence of hyponatremia, encephalopathy did not show progressive 
increase as the stage of CKD progressed. This poor correlation with the 
stages of CKD in hyponatremia and encephalopathy could be due to 
limited sample size. 
The rural patients were lost to follow up as compared to urban 
population due to increased indirect expenses and social stigma 
associated with the Geriatric population. Hence forth extending 
nephrology consultation services to the rural population is essential and 
further studies focusing on the factors contributing to the follow up 
attenuation and factors that could be done to improve the follow up. 
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ANNEXURES 
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  ABBREVIATIONS USED IN TEXT 
CKD - Chronic kidney disease 
AER - Albumin excretion rate 
NKF - National Kidney Foundation 
KDOQI - kidney Disease Outcome Qualitative Initiative 
KDIGO - Kidney Disease: Improving Global Outcomes 
GFR - Glomerular Filtration Rate 
eGFR - Estimated Glomerular Filtration Rate 
MDRD - Modification of Diet in Renal Disease 
CKD- EPI - Chronic Kidney Disease Epidemiology Collaboration 
ADPKD - Autosomal dominant polycystic kidney disease 
ACE - Angiotensin Converting Enzyme 
ARB - Angiotensin Receptor Blocker 
PCR - Protein Creatinine Ratio 
RRT - Renal Replacement Therpay 
AVF - Arterio Venous Fistula 
ESRD – End Stage Renal Disease 
DM – Diabetes Mellitus 
AGEP – Advanced Glycation End Product 
MPGN – Membranoproliferative Glomerulonephritis. 
MMSE – Mini Mental State Examination 
ESA – Erythropoietic Stimulating Agents 
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PROFORMA  
STUDY OF CKD IN GERIATRIC POPULATION – ETIOLOGY, 
CLINICAL PROFILE AND OUTCOME 
 
NAME OF THE PATIENT : 
AGE / SEX    : 
IP/OP NUMBER   : 
OCCUPATION   : 
ADDRESS    : 
 
CONTACT NUMBER  : 
CARE GIVER                        : 
 
COMPLAINTS   : 
PAST HISTORY   :     Diabetes mellitus: 
                   Systemic hypertension: 
                   H/O acute kidney injury: 
                   Others: 
TREATMENT HISTORY:   Alternative medicine intake : 
                   NSAID use : 
DRUG ALLERGY  : 
PERSONAL HISTORY :  Smoking :   Alcohol: 
               Other substance abuse: 
GENERAL EXAMINATION : 
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BMI (Quetlet’s index) : 
Weight :      Height : 
VITALS : 
Blood Pressure:     Pulse Rate: 
Respiratory Rate:     Temperature: 
Ambulant   :   Yes / No 
SYSTEMIC EXAMINATION 
CARDIOVASCULAR SYSTEM: 
RESPIRATORY SYSTEM   : 
ABDOMEN             : 
CENTRAL NERVOUS SYSTEM: Dementia & cognitive assessment 
- MMSE: 
Mini cog test:   
Eye & Fundus Examination: 
Ear & Hearing Assessment: 
Presence of severe joint disease (if present): 
Duration of CKD : 
Presence of :    
Fraility -(Assessed by Cardiovascular health study index)  
Falls & falls risk assessment -          
Urinary incontinence -  
INVESTIGATIONS: 
Hemogram :   
 
 
! 127!
LFT: 
Urinalysis :      
Fasting Lipid Profile 
RENAL FUNCTION TEST : Creatinine -  
           Blood urea nitrogen -  
eGFR:  
Cockroft Gault -    MDRD -      CKD EPI -  
Stage of CKD: 
Cockroft Gault -    MDRD -    CKD EPI - 
Ultrasound Abdomen: 
Complications at presentation :  Acute on chronic kidney disease -  
     Acute pulmonary edema -  
     Acidosis -  
     Hyperkalemia -  
     Encephalopathy -  
     Pericarditis 
Arterial blood gas:     pH                 -  
                pCO2            - 
               Bicarbonate   - 
               Anion Gap     - 
Serum electrolytes:  Serum Sodium - 
     Serum Potassium- 
Ejection Fraction   : 
ECG : 
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Chest Xray : 
Viral Markers: HbsAg -              antiHCV -    HIV - 
Special investigation (if any of the folllowing done) 
  CT / MRI Abdomen -     
  Renal Biopsy -  
  Others (if any done) -  
Renal Replacement Therapy (RRT) : Yes / No             If yes,  
(i) Mode of RRT : Hemodialysis / Peritoneal dialysis / both 
(ii) Centre for RRT : 
(iii) Frequency of RRT : 
(iv) Funding : Institutional / Insurance / Private 
(v) Vascular access if patient is on hemodialysis : 
ETIOLOGY :  Diabetes Mellitus -  Hypertension - 
     Chronic Glomerulonephritis - 
     Chronic Interstitial Nephritis - 
     Myeloma -   
     Obstructive Uropathy- 
     Ischemic nephropathy -  
     Others (mention the cause)    Unknown – 
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MINI COG TEST 
Pt. Name:______________________ DOB:_______________________ 
Date:__________________________ 
Instructions 
11.! Instruct the patient to listen carefully and repeat the following 
 
2.  Administer the Clock Drawing Test. Inside the circle draw the hours 
of a clock. Place the hands of the clock to represent the time “10 minutes 
past 11”  
3.  Ask the patient to repeat the three words given previously 
      _________         _________  __________ 
 
 
 
 
 
 
 
 
 
 
 
Score in Word Recall : 
Score in CDT  : 
Interpretation  : 
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

Write a sentence : 
Copy the design : 
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FRAILTY INDEX: 

OSTEOPOROTIC FRACTURE INDEX: 
12.!Weight loss of 5 percent in last year 
13.! Inability to rise from a chair five times without use of arms, or 
14.!A "no" response to the question "Do you feel full of energy?” 
INTERPRETATION! 
2 or more  - Frailty 
1   - Pre Frailty 
0  - No frailty 
FALLS RISK 

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
TURNITIN – PLAGIARISM – SCREENSHOT 




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INFORMATION SHEET                                                                                                                                                                                                                                                                                                                                                                                                    
 
We are conducting a study on  “STUDY OF CHRONIC KIDNEY 
DISEASE IN GERIATRIC POPULATION - ETIOLOGY, CLINICAL 
PROFILE AND OUTCOME” among patients attending Rajiv Gandhi 
Government General Hospital, Chennai  
 
The purpose of this study is to assess “Etiology, clinical profile and 
outcome in patients with chronic kidney disease in geriatric population” 
 
We are selecting certain cases and if you are found eligible, we 
may be using clinical profile, lab test reports and radiological reports for 
study purposes which does not affect your final report or management. 
 
The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or presentation 
resulting from the research, no personally identifiable information will be 
shared. 
 
Taking part in this study is voluntary. You are free to decide 
whether to participate in this study or to withdraw at any time; your 
decision will not result in any loss of benefits to which you are otherwise 
entitled. 
 
The results of the special study may be intimated to you at the end 
of the study period or during the study if anything is found abnormal 
which may aid in the management or treatment. 
 
 
 
Signature of Investigator   Signature of Participant / Guardian 
 
 
Date : 
Place : 
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PATIENT CONSENT FORM 
 
Patient may check () these boxes 
 
 
 
 
Signature of Investigator     Signature/thumb impression 
Study Investigator’s Name:   Patient’s Name and Address: 
DR. GUHAN R 
ஆராyc& ஒp)தl க-தm 
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NAME AGE GENDER LOCATION FOLLOW UP DIABETES 
MELLITUS
DURATION OF 
DIABETES (IN 
YRS)
DIABETIC 
RETINOPATHY
Boopalan 66 M CHENNAI - Y 22 NPDR
Kondaiah 65 M OUTSIDE 
CHENNai
- N - -
Perumal 75 M OUTSIDE 
CHENNai
Y N - -
Raja 68 M CHENNAI Y Y 8 NPDR
Vasantha Kumari 62 F OUTSIDE 
CHENNai
- Y 10 NPDR
Ramayi 61 F OUTSIDE 
CHENNai
Y N - -
Angusamy 80 M OUTSIDE 
CHENNai
- N - -
Munusamy 60 M CHENNAI - N - -
Parvathy 60 F CHENNAI Y Y 6 NPDR
Selvi 64 F OUTSIDE 
CHENNai
Y N - -
Abdul Jaffar 62 M CHENNAI Y N - -
Ramaih 70 F CHENNAI Y N - -
Shanthi 65 F OUTSIDE 
CHENNai
Y N - -
Savitri 60 F OUTSIDE 
CHENNai
- N - -
Shenbagavalli 63 F CHENNAI - Y 7 NPDR
Parameshwari 65 F CHENNAI - Y 10 NPDR
Jagadishwari 60 F OUTSIDE 
CHENNai
- Y 7 -
Selvam 60 M CHENNAI - Y 0.5 -
Elizabeth 70 F CHENNAI Y Y 1 -
Subhamma 60 F CHENNAI N N - -
Poongothai 67 F OUTSIDE 
CHENNai
- Y 15 NPDR
Angaiyan 62 M CHENNAI Y N - -
Kuppammal 65 F CHENNAI - Y 7 NPDR
Panjammal 70 F OUTSIDE 
CHENNai
Y Y 9 NPDR
Ranganathan 63 M OUTSIDE 
CHENNai
N Y 5 NPDR
Vasantha 65 F CHENNAI - N - -
Sakunthala 70 F  CHENNAI Y N - -
Periasamy 70 M CHENNAI Y N - -
Pandi 60 M CHENNAI N N - -
Ramu 69 M OUTSIDE 
CHENNai
Y Y 4 NPDR
Chinnaponnu 70 F OUTSIDE 
CHENNai
- N - -
Vazeer Baasha 78 M CHENNAI - Y 10 -
Prakash 60 M CHENNAI Y Y 5 NPDR
Vasantha 60 F OUTSIDE 
CHENNai
N Y 6 NPDR
Periyasamy 78 M OUTSIDE 
CHENNai
Y N - -
Vanitha 79 F CHENNAI N Y 20 -
Krishnakumari 65 F CHENNAI - Y 20 NPDR
Murugesan 60 M OUTSIDE 
CHENNai
Y N - -
Petchiyammal 62 F OUTSIDE 
CHENNai
N Y 10 NPDR
Gopal 60 M OUTSIDE 
CHENNai
N N - -
Sunthari 62 F CHENNAI - Y 10 NPDR
Saraswathi 65 F CHENNAI Y N - -
Lakshmi 69 F CHENNAI Y Y 5 NPDR
Mohammed 
Hussaun
62 M OUTSIDE 
CHENNai
Y Y 12 NPDR
Chinnayyan 63 M CHENNAI - Y 4 -
Sambasivam 70 M CHENNAI Y Y 6 -
Alankaram 67 F CHENNAI - N - -
Egambaram 77 M CHENNAI Y Y 1 -
Dharman 70 M OUTSIDE 
CHENNai
- Y 5 -
Parthasarathy 62 M OUTSIDE 
CHENNai
Y Y 20 NPDR
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Dhanapal 62 M CHENNAI - Y 20 NPDR
Lakshmi 60 F CHENNAI Y N - -
Ellaiyammal 65 F OUTSIDE 
CHENNai
- Y 3 -
Ramamoorthy 60 M CHENNAI Y Y 4 -
Kuppusamy 62 M CHENNAI Y N - -
Dhanalakshmi 68 F OUTSIDE 
CHENNai
N Y 10 NPDR
Poongavanam 67 F CHENNAI - Y 0.5 NPDR
Fathima 70 F CHENNAI Y N - -
Babu 60 M OUTSIDE 
CHENNai
N Y 5 NPDR
Anbumani 61 F OUTSIDE 
CHENNai
N Y 25 NPDR
Indrani 65 F CHENNAI Y Y 2 NPDR
Sampath 61 M OUTSIDE 
CHENNai
- N - -
Krishnaveni 60 F CHENNAI Y Y 11 NPDR
Ravi 64 M OUTSIDE 
CHENNai
N N - -
Davlath Ram 78 M CHENNAI Y Y 8 -
Ravi 60 M CHENNAI N Y 7 NPDR
Indirani 74 F CHENNAI - Y 1 -
Kamala 60 F CHENNAI N Y 17 NPDR
Duraimani 66 M CHENNAI - Y 10 NPDR
Saida 61 F CHENNAI Y Y 5 -
Valiyammal 65 F CHENNAI Y Y 20 -
Goundhan 62 M OUTSIDE 
CHENNai
- Y 10 NPDR
Kalathari 65 F CHENNAI N Y 7 NPDR
Ravi 61 M OUTSIDE 
CHENNai
N Y 5 -
Rajammal 60 F CHENNAI Y Y 5 -
Gangaiammal 65 F CHENNAI - Y 6 NPDR
Chellamal 70 F CHENNAI Y Y 10 -
Gajalakshmi 60 F CHENNAI Y N - -
Valliyammal 62 F OUTSIDE 
CHENNai
- N - -
Gangammal 60 F CHENNAI - Y 30 -
Janardhanan 61 M CHENNAI - Y 18 NPDR
Velan 70 M OUTSIDE 
CHENNai
Y Y 10 -
Ezhumalai 67 M OUTSIDE 
CHENNai
N N - -
Murugesan 74 M CHENNAI Y N - -
Jayaraj 60 M OUTSIDE 
CHENNai
- Y 15 -
Mani 60 M OUTSIDE 
CHENNai
N Y 12 NPDR
Venkatammal 64 F CHENNAI - N - NPDR
?Arunmiyam 65 M OUTSIDE 
CHENNai
N Y 5 -
Rani 67 F CHENNAI - Y 20 PDR
Rajendran 66 M CHENNAI Y N - -
Ponnamal 66 F OUTSIDE 
CHENNai
N Y 8 NPDR
Mary 61 F CHENNAI Y N - -
Muniyammal 75 F OUTSIDE 
CHENNai
- N - -
Jyothi 60 F OUTSIDE 
CHENNai
- N - -
kuppusamy 66 M OUTSIDE 
CHENNai
- N - -
Mani 68 M OUTSIDE 
CHENNai
N Y 8 B/L NPDR
Munimmal 64 F OUTSIDE 
CHENNai
- N - -
Radha 65 F CHENNAI - Y 6 -
Raniammal 62 F OUTSIDE 
CHENNai
N N - -
Nagarajan 65 M CHENNAI Y Y 5 NPDR
AGE GENDER LOCATION FOLLOW UP DIABETES 
MELLITUS
DURATION OF 
DIABETES (IN 
YRS)
DIABETIC 
RETINOPATHY
NAME
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SYSTEMIC HTN DURATION OF 
SYSTEMIC HTN 
(IN YRS)
PRESENCE OF 
HYPERTENSIVE 
RETINOPATHY
SMOKER ALCOHOLIC DURATION OF 
CKD (IN YRS)
CREATININE (MG/
DL)
N N N 2 3
N Y N 1 1.4
Y 4.5 N N 1 3
Y 6 Y Y Y 1 3.2
Y 5 Y N N 3 1.9
Y 1 N N 1 22.9
N Y Y 6 8.7
Y 2 N Y 2 9.4
Y 6 N N 1 1.8
Y 4 Y N N 1 8.3
Y 2 Y Y 0.5 7.6
N N N 0.25 22.8
N N N 0.5 6.1
Y 0.5 Y N N 0.75 7.7
Y 7 N N 1 6.9
Y 2 N N 1 5.9
Y 1 N N 0.5 9.5
N N Y 9 2.4
Y 1 N N 1 3.2
Y 1 N N 1 5.1
Y 7 Y N N 5 6.4
N Y Y 1 3
Y 5 N N 1 1.9
Y 0.5 N N 1 3.4
Y 5 Y Y 3 10.4
Y 8 N N 8 12.1
Y 10 Y N N 1 2.6
Y 5 N Y 1 1.7
Y 20 Y N Y 1 1.5
Y 1 N N 0.5 12.7
Y 1 N N 0.25 3.7
Y 10 N N 0.5 1.6
Y 3 N N 3 9.7
Y 6 N N 1 2.2
N N N 0.5 5.3
N N N 0.5 1.4
Y 10 N N 5 3.4
Y 5 Y N Y 1 3
Y 4 N N 2 2.3
Y 1 N N 0.5 5.1
N N N 1 4.1
N N N 2 2.1
N N N 1 1.3
Y 0.75 Y N 0.5 4.5
Y 2 N Y 1 4.9
Y 3 N N 1 2.3
N N N 0.5 2.6
N Y N 1 2.4
N N N 1 1.4
Y 0.75 N Y 1.5 7.7
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Y 0.25 Y Y 0.75 19
Y 14 N N 1 1.4
Y 3 N N 1 4.2
Y 4 Y Y 1 9.7
N Y Y 3 5
Y 10 N N 2 1.9
N N N 0.5 2.8
N N N 0.5 4.6
Y 1 Y N 1 1.7
Y 20 Y N N 1 1.6
Y 0.5 N N 0.5 1.7
Y 14 Y Y N 14 8.2
Y 3 N N 0.5 1.4
N N Y 0.5 3.6
Y 8 N N 2 3.5
Y 4 N Y 2 1.7
Y 1 N N 1 2.8
Y 3 N N 0.25 2.2
Y 5 Y Y 2 6.6
Y 5 N N 0.5 1.6
N N N 1 1.9
Y 8 N Y 3 4.3
N N N 0.25 1.5
Y 5 Y Y Y 0.25 3.6
Y 3 Y Y 0.25 2.4
Y 2 N N 1 3.6
Y 10 N N 0.25 7.1
Y 5 N N 0.25 1.5
N N N 0.75 2.5
Y 10 N N 1 4.9
Y 0.75 N N 0.75 7.9
Y 10 N N 2 8.5
Y 3 Y N N 1 1.4
Y 14 Y N Y 1 2.7
Y 15 Y Y Y 2 4.4
Y 8 Y Y Y 0.75 1.4
Y 0.5 N N 0.5 2.9
Y 5 Y Y 0.5 3.2
Y 20 Y N N 0.5 2.7
N N N 0.25 3.2
Y 8 N N 1 1.7
Y 10 Y N N 1 2.2
Y 5 N N 2 4.1
N N N 1.5 3.3
Y 3 Y Y 1.5 3.4
Y 3 Y N 2 2.9
Y 3 N N 1 2.6
Y 2 N N 2 3.4
N N 1.5 1.9
Y 3 N N 1 1.8
SYSTEMIC HTN DURATION OF 
SYSTEMIC HTN 
(IN YRS)
PRESENCE OF 
HYPERTENSIVE 
RETINOPATHY
SMOKER ALCOHOLIC DURATION OF 
CKD (IN YRS)
CREATININE (MG/
DL)
Dhanapal
Lakshmi
Ellaiyammal
Ramamoorthy
Kuppusamy
Dhanalakshmi
Poongavanam
Fathima
Babu
Anbumani
Indrani
Sampath
Krishnaveni
Ravi
Davlath Ram 
Ravi
Indirani
Kamala
Duraimani
Saida
Valiyammal
Goundhan
Kalathari
Ravi
Rajammal
Gangaiammal
Chellamal
Gajalakshmi
Valliyammal
Gangammal
Janardhanan
Velan
Ezhumalai
Murugesan
Jayaraj
Mani
Venkatammal
?Arunmiyam
Rani
Rajendran
Ponnamal
Mary 
Muniyammal
Jyothi
kuppusamy
Mani
Munimmal
Radha
Raniammal
Nagarajan
NAME
MASTER CHART
 4
STAGING OF CKD 
by CKD - EPI
Weight Height (in cm) Height (in m) BMI Underweight AMBULANT
4 68 170 1.7 23.5294117647059 N N
3a 62 170 1.7 21.4532871972318 N Y
4 62 168 1.68 21.9671201814059 N N
4 80 168 1.68 28.3446712018141 N N
4 32 146 1.46 15.0121974103959 Y Y
5 52 152 1.52 22.5069252077562 N Y
5 42 166 1.66 15.2416896501669 Y Y
5 45 164 1.64 16.7311124330756 Y N
3b 41 155 1.55 17.0655567117586 Y Y
5 45 162 1.62 17.1467764060357 Y N
5 49 168 1.68 17.3611111111111 Y Y
5 46 162 1.62 17.5278158817253 Y N
5 47 163 1.63 17.6897888516692 Y N
5 50 168 1.68 17.7154195011338 Y N
5 53 172 1.72 17.9150892374256 Y Y 
5 48 162 1.62 18.2898948331047 N N 
5 58 178 1.78 18.3057694735513 N Y
4 45 156 1.56 18.491124260355 N Y
5 51 166 1.66 18.5077660037741 N Y
5 44 153 1.53 18.796189499765 N Y
5 56 172 1.72 18.9291508923743 N N
4 52 164 1.64 19.3337299226651 N N
4 45 151 1.51 19.7359764922591 N Y
5 52 162 1.62 19.8140527358634 N Y
5 58.4 168 1.68 20.6916099773243 N N
5 48 152 1.52 20.7756232686981 N N
4 55 162 1.62 20.9571711629325 N Y
3b 55 162 1.62 20.9571711629325 N Y
3a 55 168 1.68 19.4869614512472 N Y
5 58 166 1.66 21.0480476121353 N Y
5 58 166 1.66 21.0480476121353 N N
3b 60 168 1.68 21.2585034013605 N N 
5 50 153 1.53 21.359306249733 N Y
4 58 164 1.64 21.5645449137418 N N
5 61 168 1.68 21.6128117913832 N Y
3b 52 155 1.55 21.6441207075963 N N
5 60 166 1.66 21.7738423573813 N Y
4 56 160 1.6 21.875 N Y
4 52 154 1.54 21.9261258222297 N Y
5 65 172 1.72 21.9713358572201 N N
5 55 158 1.58 22.0317256849864 N N
4 51 152 1.52 22.0740997229917 N Y
3b 58 162 1.62 22.1002895900015 N N
5 64 170 1.7 22.1453287197232 N N
5 70 176 1.76 22.5981404958678 N N
4 65 168 1.68 23.0300453514739 N Y
5 62 164 1.64 23.051754907793 N N
4 62 164 1.64 23.051754907793 N N
3a 72 175 1.75 23.5102040816327 N N 
5 68 170 1.7 23.5294117647059 N N
Boopalan
Kondaiah
Perumal
Raja
Vasantha Kumari
Ramayi
Angusamy
Munusamy
Parvathy
Selvi
Abdul Jaffar
Ramaih
Shanthi
Savitri
Shenbagavalli
Parameshwari 
Jagadishwari
Selvam
Elizabeth
Subhamma
Poongothai
Angaiyan
Kuppammal
Panjammal
Ranganathan
Vasantha
Sakunthala 
Periasamy
Pandi 
Ramu
Chinnaponnu
Vazeer Baasha
Prakash
Vasantha
Periyasamy
Vanitha
Krishnakumari
Murugesan
Petchiyammal
Gopal
Sunthari
Saraswathi
Lakshmi
Mohammed 
Hussaun
Chinnayyan
Sambasivam
Alankaram
Egambaram
Dharman
Parthasarathy
NAME
MASTER CHART
 5
5 72 174 1.74 23.7812128418549 N Y
3b 72 174 1.74 23.7812128418549 N N
5 58 156 1.56 23.8330046022354 N N
5 76 178 1.78 23.9868703446535 N Y
5 78 180 1.8 24.0740740740741 N Y
4 58 168 1.68 20.5498866213152 N Y
5 62 167 1.67 22.2309871275413 N N
5 62 160 1.6 24.21875 N Y
3b 70 170 1.7 24.2214532871972 N Y
3b 54 148 1.48 24.6530314097882 N Y
3b 65 162 1.62 24.7675659198293 N Y
5 65 162 1.62 24.7675659198293 N Y
3b 62 158 1.58 24.8357634994392 N Y
4 63 174 1.74 20.8085612366231 N N
4 65 176 1.76 20.9839876033058 N N
3b 68 172 1.72 22.9853975121687 N Y
4 75 172 1.72 25.3515413737155 N y
4 63 168 1.68 22.3214285714286 N Y
5 75 170 1.7 25.9515570934256 N N
3b 68 170 1.7 23.5294117647059 N Y
4 56 155 1.55 23.309053069719 N Y
5 72 170 1.7 24.9134948096886 N N
3b 65 155 1.55 27.0551508844953 N Y
4 63 165 1.65 23.1404958677686 N Y
4 62 168 1.68 21.9671201814059 N Y
5 68 160 1.6 26.5625 N Y
5 82 166 1.66 29.7575845550878 N Y
3b 76 172 1.72 25.6895619253651 N Y
4 47 153 1.53 20.077747874749 N N
5 58 168 1.68 20.5498866213152 N Y
5 56 174 1.74 18.4964988769983 N N
5 53 172 1.72 17.9150892374256 Y ?
3a 48 165 1.65 17.6308539944904 Y Y
4 58 163 1.63 21.8299521999323 N Y
5 78 168 1.68 27.6360544217687 N Y
3a 72 172 1.72 24.3374797187669 N Y
4 58 166 1.66 21.0480476121353 N N
4 70 166 1.66 25.4028160836116 N Y
4 48 168 1.68 17.0068027210884 Y Y
4 62 170 1.7 21.4532871972318 N N
3b 65 168 1.68 23.0300453514739 N Y
4 40 158 1.58 16.0230732254446 Y
5 38 156 1.56 15.6147271531887 Y Y
5 72 168 1.68 25.5102040816327 N N
4 48 172 1.72 16.2249864791779 Y N
4 55 168 1.68 19.4869614512472 N y
4 52 162 1.62 19.8140527358634 N Y
5 48 165 1.65 17.6308539944904 Y N
4 58 166 1.66 21.0480476121353 N Y 
3b 72 172 1.72 24.3374797187669 N Y
STAGING OF CKD 
by CKD - EPI
Weight Height (in cm) Height (in m) BMI Underweight AMBULANT
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COGNITIVE 
DYSFUNCTION 
ASSESSED BY 
MMSE
COGNITIVE 
DYSFUNCTION 
ASSESSED BY 
MINI COG TEST
B/L SNHL PRESENCE OF 
JOINT DISEASE
PRESENCE OF 
FRAILTY
FALLS RISK URINARY 
INCONTINENCE
Y Y Y  # R neck of femur 
1yr ago
YES HIGH -
N N Y B/L OA YES LOW -
NA NA Y YES HIGH -
NA NA - YES HIGH -
N N - B/L OA YES MODERATE -
N N - LOW -
N N Y YES LOW -
NA NA Y B/L OA YES HIGH -
N N Y B/L OA YES HIGH YES
NA NA - YES HIGH -
N N - YES LOW -
Y Y Y B/L OA YES MODERATE -
NA NA Y B/L OA YES HIGH -
N  N - LOW -
N   N Y LOW -
N   N   - LOW -
N N - YES LOW -
N N - B/L OA YES HIGH -
N N - HIGH -
N N - B/L OA HIGH -
NA NA - YES HIGH -
Y Y Y B/L OA YES LOW -
Y N Y B/L OA YES LOW YES
N N - B/L OA YES LOW -
NA NA - HIGH -
Y Y - YES HIGH -
N N Y B/L OA YES LOW YES
Y Y Y YES LOW -
Y Y - YES MEDIUM -
Y Y Y B/L OA YES LOW -
Y Y Y B/L OA YES LOW YES
Y Y Y B/L OA YES HIGH YES
N N - YES HIGH -
N N - B/L OA YES HIGH -
N N - YES MODERATE -
Y Y - B/L OA YES LOW -
N N - HIGH -
N N - HIGH -
Y Y Y B/L OA YES LOW -
NA NA - B/L OA YES HIGH -
NA  NA  - B/L OA YES HIGH -
N N Y YES LOW -
N N - B/L OA YES LOW YES
Y N - YES LOW -
N N - LOW -
N N - YES LOW -
N  N Y B/L OA YES LOW YES
NA NA Y B/L OA YES HIGH YES
NA  NA  - B/L OA YES HIGH -
NA NA Y B/L OA YES HIGH -
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N N - YES LOW -
NA NA Y YES HIGH -
N N - B/L OA YES LOW -
N N - YES LOW -
N N Y YES LOW -
N N - B/L OA YES LOW -
NA NA Y B/L OA YES HIGH -
Y Y - LOW -
N N - LOW -
N N Y B/L OA YES LOW -
N  N  - B/L OA YES LOW -
N N - LOW -
N N Y B/L OA YES LOW -
N N Y YES HIGH -
NA NA Y B/L OA YES HIGH -
N N Y B/L OA YES LOW -
N N - yes HIGH -
N N Y B/L OA YES LOW -
NA NA Y Osteoporosis   # L 
NOF
YES HIGH YES
N  N  Y B/L OA YES LOW -
N N - LOW -
NA NA - B/L OA YES HIGH -
N N   Y B/L OA YES LOW YES
N N - YES LOW YES
N N - YES LOW -
N N - LOW -
Y Y - LOW -
N N Y LOW -
N  N  - LOW -
N  N   - LOW -
N N Y B/L OA YES LOW -
NA NA NA YES HIGH -
N N Y YES LOW -
N N Y B/L OA YES LOW -
N N - LOW -
N N  - YES LOW -
N N - B/L OA YES LOW YES
N N Y YES LOW -
N  N Y LOW -
Y Y - YES LOW -
N N Y B/L OA YES LOW -
N N - LOW -
N N Y LOW -
N N - LOW -
N N Y B/L OA YES LOW -
N N Y YES LOW -
N N - YES LOW -
Y Y - B/L OA YES LOW YES
N N Y B/L OA YES LOW -
N N Y B/L OA YES LOW -
COGNITIVE 
DYSFUNCTION 
ASSESSED BY 
MMSE
COGNITIVE 
DYSFUNCTION 
ASSESSED BY 
MINI COG TEST
B/L SNHL PRESENCE OF 
JOINT DISEASE
PRESENCE OF 
FRAILTY
FALLS RISK URINARY 
INCONTINENCE
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HEMOGLOBIN TYPE OF ANEMIA 
(M- 
MICROCYTOSIS; 
N- NORMOCYTIC)
MEAN 
CORPUSCULAR 
VOLUME
SGOT SGPT ALKALINE 
PHOSPHATASE
CREATININE
10 N 80.1 13 11 331 3
8.4 N 80.4 13 15 104 1.4
11.7 N 85.9 13 11 62 3
5.3 N 87.1 36 21 21 3.2
8.4 M 78.3 13 14 78 1.9
5.7 N 85.5 12 10 156 22.9
7.8 M 74 18 16 45 8.7
6.5 N 84.7 13 11 34 9.4
12.9 N 82.9 17 18 72 1.8
5.9 M 78.9 27 29 110 8.3
6.4 N 85.5 18 62 110 7.6
5.7 N 85.5 12 10 22.8
9.6 M 74 16 19 112 6.1
6.8 N 90 104 54 127 7.7
11.8 M 76 30 22 99 6.9
8.7 N 93.1 13 16 88 5.9
8.1 M 75 17 14 59 9.5
9.9 M 76.4 19 18 356 2.4
10.2 N 83.3 18 22 77 3.2
8 N 88.6 18 17 165 5.1
7.4 N 83.3 20 19 116 6.4
6.5 N 89.8 17 18 140 3
10.3 M 77.6 31 43 43 1.9
5.5 M 57 20 14 122 3.4
6.8 M 68 16 18 98 10.4
5.8 M 77.8 29 35 143 12.1
7.8 N 94.8 21 17 78 2.6
10.2 N 82 40 36 117 1.7
14.4 N 97 23 26 49 1.5
6.3 N 91.3 21 24 57 12.7
11 N 85.4 27 29 153 3.7
12 N 84.6 23 21 151 1.6
5.8 N 82 8 7 470 9.7
9.7 N 84.2 13 11 72 2.2
8.5 M 74 20 21 82 5.3
11.3 N 87 11 13 117 1.4
8.7 N 84.6 62 38 150 3.4
7.6 M 72.4 24 26 28 3
12 N 84.6 17 11 70 2.3
9.6 N 91.8 18 30 106 5.1
8.1 N 82.7 12 18 125 4.1
8 M 73.4 14 14 145 2.1
9.9 N 83.5 25 30 71 1.3
13.7 N 90 11 20 177 4.5
7.5 M 68 29 13 62 4.9
10.2 N 88.8 16 24 66 2.3
8.2 M 55.6 12 31 90 2.6
12.5 N 84.3 81 48 60 2.4
11.2 N 86.4 14 13 48 1.4
9.6 N 89.8 29 24 174 7.7
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7.2 M 78 14 12 19
12.1 N 82.7 20 57 50 1.4
6.8 M 79.6 26 23 56 4.2
6.6 M 64.2 12 16 16 9.7
7.9 N 94.2 31 33 67 5
9.9 N 82.8 18 19 79 1.9
8 M 78 30 45 75 2.8
12.4 N 83.5 86 24 106 4.6
8.9 M 77.4 14 13 94 1.7
8.5 N 84.4 14 14 87 1.6
10.9 N 97.7 17 30 82 1.7
7.8 M 62.5 16 12 96 8.2
11.9 N 82.4 11 9 135 1.4
8.4 N 102.4 26 33 184 3.6
12 N 83.4 24 24 65 3.5
10.1 N 91.3 33 25 98 1.7
9.8 N 85.4 17 19 98 2.8
10 N 90.8 19 22 122 2.2
9 N 80.8 36 25 54 6.6
10.1 N 99.2 65 75 92 1.6
8.6 M 75.4 24 28 30 1.9
11.5 N 84.6 18 16 57 4.3
10.2 N 84 33 11 68 1.5
8.4 M 75.5 26 33 184 3.6
10.1 N 84.4 24 21 49 2.4
5.8 M 72.2 12 11 246 3.6
6.2 N 84 20 20 71 7.1
6.1 M 73.3 17 22 76 1.5
6.9 N 86.4 35 18 156 2.5
5.8 N 92.1 13 16 179 4.9
7.2 N 83.6 35 46 26.6 7.9
9.9 N 85.7 13 11 79 8.5
11 M 78.6 125 133 105 1.4
11.3 N 88.6 13 12 36 2.7
11.3 N 86.4 23 28 123 4.4
11.9 N 91.6 20 20 100 1.4
13.2 N 84 30 32 115 2.9
9.2 N 82 16 18 97 3.2
8.8 M 78 39 86 185 2.7
13.4 86.6 29 14 164 3.2
14.3 N 82.7 18 16 148 1.7
13.4 N 84.4 37 16 16 2.2
8.8 N 83.6 22 18 136 4.1
10.3 N 86.4 32 36 232 3.3
8.1 N 84 16 12 102 3.4
9.8 N 82 17 15 97 2.9
9.6 N 85 18 16 112 2.6
7.2 M 72 26 28 108 3.4
9.2 M 76 14 12 96 1.9
8.8 N 84 16 13 106 1.8
HEMOGLOBIN TYPE OF ANEMIA 
(M- 
MICROCYTOSIS; 
N- NORMOCYTIC)
MEAN 
CORPUSCULAR 
VOLUME
SGOT SGPT ALKALINE 
PHOSPHATASE
CREATININE
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eGFR estd by 
COCKROFT 
GAULT FORMULA
EGFR ESTD BY 
MDRD FORMULA
eGFR ESTD BY 
CKD - EPI 
FORMULA
STAGE OF CKD 
ACC TO 
COCKROFT 
GAULT FORMULA
STAGE OF CKD 
ACC TO MDRD 
FORMULA
STAGE OF CKD 
ACC TO CKD - EPI 
FORMULA
ACUTE ON 
CHRONIC KIDNEY 
DISEASE
23.2962962962963 22.4 20.7 4 4 4
46.1309523809524 54.1 52.4 3b 3a 3a
18.6574074074074 21.8 19.4 4 4 4
25 20.6 18.9 4 4 4 YES
15.5087719298246 28.5 27.8 4 4 4
2.11778262979136 1.6 1.4 5 5 5 YES
4.02298850574713 6.3 5.2 5 5 5 YES
5.31914893617021 6.1 5.4 5 5 5 YES
21.5123456790123 30.5 30.1 4 3b 3b
4.8644578313253 5.2 4.6 5 5 5 YES
6.98464912280702 7.7 6.9 5 5 5 YES
1.66727582846004 1.6 1.3 5 5 5 YES
6.82206284153005 7.3 6.6 5 5 5 YES
6.13275613275613 5.7 5.2 5 5 5 YES
8.21457326892109 6.4 5.8 5 5 5 YES
7.20338983050847 7.6 6.9 5 5 5 YES
5.76608187134503 4.5 4 5 5 5 YES
20.8333333333333 29.5 28.3 4 4 4
13.1705729166667 15.2 14.0 5 4 5 YES
8.14814814814815 9.2 8.5 5 5 5 YES
7.54079861111111 6.9 6.2 5 5 5 YES
18.7777777777778 22.6 21.3 4 4 4
20.9703947368421 28.2 27.2 4 4 4
12.6388888888889 14.2 13.0 5 5 5
6.00534188034188 5.4 4.7 5 5 5 YES
3.51239669421488 3.3 2.9 5 5 5 YES
20.5662393162393 19.3 18.0 4 4 4
31.4542483660131 42.6 40.0 4 3b 3b
40.7407407407407 50.7 49.9 3b 3a 3a
4.50349956255468 4.2 3.5 5 5 5 YES
12.9542042042042 12.9 11.7 5 5 5
32.2916666666667 44.7 40.7 4 3b 3b
5.72737686139748 5.9 5.2 5 5 5
24.8989898989899 24.2 23.6 4 4 4
9.91090146750524 11.2 9.6 5 5 5
26.7480158730159 38.6 35.6 4 3b 3b
18.3823529411765 14.4 13.5 4 5 5
20.7407407407407 22.8 21.6 4 4 4
20.8188405797101 22.8 22.0 4 4 4
14.161220043573 12.4 11.4 5 5 5 YES
12.3526422764228 11.7 11.0 5 5 5
21.5029761904762 25.1 24.1 4 4 4
37.3963675213675 43.2 41.8 3b 3b 3b
15.4074074074074 14.2 13.0 5 5 5 YES
15.2777777777778 12.8 11.7 5 5 5
27.475845410628 30.0 27.7 4 4 4
20.5507478632479 19.5 18.3 4 4 5
22.6041666666667 28.0 25.1 4 4 4 YES
50 53.3 50.5 3b 3a 3a
9.56709956709957 7.6 6.8 5 5 5 YES
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4.10526315789474 2.7 2.3 5 5 5 YES
48.5714285714286 40.8 40.7 3b 3b
12.2271825396825 11.3 10.4 5 5 5 YES
8.70561282932417 5.9 5.2 5 5 5 YES
16.9 12.6 11.5 5 5 5 YES
25.9473684210526 27.9 26.6 4 4 4
19.0828373015873 17.9 16.8 4 4 5 YES
11.1382850241546 10.0 9.0 5 5 5 YES
45.7516339869281 43.9 42.9 3b 3b 3b YES
31.4765625 34.8 34.4 3b 3b 3b
33.8541666666667 32.1 31.1 3b 3b 3b
8.69749322493225 7.1 6.4 5 5 5
41.8253968253968 40.8 40.7 3b 3b 3b
18.4722222222222 18.2 16.8 4 4 4
15.9920634920635 18.1 15.8 4 4 4
44.4444444444444 43.9 42.9 3b 3b 3b
20.8705357142857 17.6 16.0 4 4 4
27.0454545454545 24.2 23.6 3b 4 4
11.6792929292929 9.0 8.0 5 5 5 YES
39.6371527777778 34.8 34.4 3b 3b 3b  
26.0964912280702 28.2 27.2 4 4 4
18.1395348837209 14.9 13.8 4 5 5 YES
38.3680555555556 37.0 36.2 3b 3b 3b
19.2013888888889 18.4 17.2 4 4 4 YES
24.3981481481481 21.9 21.2 4 4 4 YES
16.724537037037 13.5 12.6 4 5 5 YES
9.54420970266041 6.1 5.3 5 5 5 YES
47.8518518518519 37.6 37.5 3a 3b 3b
20.3666666666667 20.7 19.9 4 4 4 YES
13.1519274376417 9.6 9.0 4 5 5 YES
7.77777777777778 7.4 6.6 5 5 5 YES
6.06209150326797 6.6 5.7 5 5 5 YES
34.7619047619048 53.7 51.6 4 3a 3a
19.6913580246914 24.7 22.2 4 4 4
19.6969696969697 14.7 13.6 4 5 5 YES
57.1428571428571 54.9 54.2 3a 3a 3a
17.9444444444444 17.4 16.4 4 4 4
22.7864583333333 20.8 19.3 4 4 4 YES
15.320987654321 18.7 17.5 4 4 4
19.9131944444444 20.8 19.1 4 4 4
33.4027777777778 32.0 30.9 3b 3b 3b
16.9570707070707 24.1 23.4 4 4 4 YES
7.11212737127371 11.3 10.0 5 5 5 YES
20.6060606060606 15.2 14.4 4 4 5 YES
14.5098039215686 19.4 17.8 5 4 4
18.9655172413793 23.1 21.3 4 4 4
17.9444444444444 19.7 18.7 4 4 4
12.5 14.4 13.5 5 5 5
28.109649122807 28.5 27.8 3B 4 4
41.6666666666667 40.4 38.6 3b 3b 3b
eGFR estd by 
COCKROFT 
GAULT FORMULA
EGFR ESTD BY 
MDRD FORMULA
eGFR ESTD BY 
CKD - EPI 
FORMULA
STAGE OF CKD 
ACC TO 
COCKROFT 
GAULT FORMULA
STAGE OF CKD 
ACC TO MDRD 
FORMULA
STAGE OF CKD 
ACC TO CKD - EPI 
FORMULA
ACUTE ON 
CHRONIC KIDNEY 
DISEASE
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ACUTE PULM. 
EDEMA
ACIDOSIS HYPERKALEMIA ENCEPHALOPATH
Y
PERICARDITITS OTHERS Arterial pH
YES Hypoglycemia / 
HYPOKALEMIA
7.24
YES YES A/C exacerbation of 
COPD
7.24
YES YES CVA- R MCA 
INFARCT
7.28
YES YES YES 7.51
YES 7.35
YES YES YES 7.18
YES
YES YES 7.39
YES 7.38
YES YES YES
YES YES 7.42
YES YES 7.18
YES YES 7.24
YES YES YES 7.20
YES 7.34
YES 7.34
YES 7.36
YES
YES YES YES 7.33
YES YES PTB     POTTS 
SPINE
7.35
YES YES
YES YES
YES YES YES 7.09
YES
YES
YES YES
YES YES YES 7.28
YES
Hypokalemia  
Hypokalemia 7.55
7.38
YES
YES 7.2
YES YES YES 7.26
YES YES YES 7.28
YES YES 7.25
Hypokalemia  
Hyponatremia
7.48
YES YES 7.32
YES
7.36
7.49
YES
YES YES 7.39
YES
YES YES YES YES 7.32
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YES YES 7.27
YES 7.42
YES YES YES 7.27
YES YES 7.3
YES 7.32
YES 7.34
YES YES YES 7.18
7.32
YES 7.34
YES 7.41
7.28
YES
7.45
YES
YES YES 7.42
YES
YES YES 7.26
YES 7.28
YES YES Aspiration 
pneumonitis
7.37
YES 7.39
YES YES 7.35
YES
YES 7.34
YES YES YES 7.38
7.38
YES YES YES 7.30
7.38
YES Uremic gastritis
YES YES YES
YES YES YES YES 7.38
YES
7.42
YES 7.37
YES
7.5
YES
YES 7.28
7.38
7.48
YES YES YES 7.22
YES YES YES 7.3
YES 7.32
YES YES YES 7.26
ACUTE PULM. 
EDEMA
ACIDOSIS HYPERKALEMIA ENCEPHALOPATH
Y
PERICARDITITS OTHERS Arterial pH
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pCO2 Bicarbonate Anion Gap Serum Sodium Serum Potassium Ejection Fraction LVSD
18 16 22 141 2.8 50% mild
52 20 18 140 5.5 60% -
22 16 18 144 4.4 61% -
16.7 16.7 20.4 125 4.1 54% mild
33.1 17.9 17.9 128 4.9
16.2 7.7 28.8 128 5.6
136 5.9
24.3 16.7 21.8 120 3.1
30.9 18.7 19
141 3.1
24.9 17.8 34.6 134 3.9
16.2 7.7 25.1 128 5.8
12.2 10.1 21.6 118 2.8
121 3.7
29.5 12.6 27.1 130 5.4
21.5 11.3 26.2 138 4.4
24.8 13.1 21.3 131 4.8 65% -
133 3.6
30.2 17.9 21 139 4.5 65% -
140 5 48% mild
25.7 15.1 22 135 4.7
15.9 12 22.7 132 5.5
133 3.4 63% 0
140 6.4
135 5.0 47% mild
22 7.5 30.7 136 5.7
136 5 35% severe
138 3.6 30% severe
139 5.4
22 14 18 135 6.1
139 6.2 64% -
134 2.2 51% mild
142.6 5.5
45.3 39.2 32.6 137 1.7
142 4.9
36 22 15 138 4.5 47% mild
159 3.4
18.3 13.4 22 142 4.4
25.3 13.2 29.4 136 7 50% mild
26 16 16 141 5.7
28.8 12.2 26 118 4.7
30.7 22.6 17.1 113 2.6 70% -
14 16 18 142 4.9 50% mild
142 4.1 38% moderate
26 18 21 129 4.1 65% -
34.1 26.4 13.2 138 4.9 51% mild
138 5.1
29.3 17.3 20.2 122 3.7
136 4.7 65% -
21.5 10.7 24.3 127 5.4 45% mild
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18 8 20 143 4.4 65% -
36 22 14 143 4.1 64% -
22 16 22 130 7.5 47% mild
24.1 13.4 21.8 138 4.9 60% -
28 18 22 131 4.6 64 -
25 15.7 28.7 135 4.5 65% -
19 14 24 130 5.2
39 20 13.2 130 4.1 66% -
35.4 18.8 131 4.2 49% mild
40 24.6 14.2 142 4.1 41% moderate
42 23 12 138 4 60% -
130 6.2
33.3 22.5 18 132 4.7
141 3
30.0 18 18 137 4.4 55% mild
136 4.3 20% severe
24 14 17 143 5.8
27 12.3 24.5 137 3.9 50% mild
23.6 13.3 26.5 140 4.4
132 3.9
19.3 11.4 24.5 145 5
29.3 17.3 20.8 145 3.6
125 4.8 60% -
46 19 14 141 3 56% -
36 26 14.2 143 4.4 60% -
40 18 14.2 141 4.7 60% -
42 14 16 135 6.6 45% mild
46 21.2 18.6 138 4.6 46% mild
140 3.2
141 4.7 55% mild
145 5.7
27 15.4 18.7 139 6.2 63%
141 2.8 48% mild
34 21.6 10.9 139 4.8
24.6 15.7 21.8 130 4.6 50% mild
139 3.9 30% severe
19.1 20.7 20 123 3.8
135 4.8
133 4.5 70% -
136 4.1 70% -
26 15 16 148 3.4
137 2.7
36.8 21.0 5.2 140 5.0 60% -
24 12.9 13.5 138 5.7
14 12 18 131 5.8 48% mild
22 16 19 132 5.6 45% moderate
28 16 18 138 4.8 62% -
18 12 24 131 5.8 42% mild
42% moderate
pCO2 Bicarbonate Anion Gap Serum Sodium Serum Potassium Ejection Fraction LVSD
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RENAL 
REPLACEMENT 
THERAPY
HD / PD / HD AND 
PD
CENTRE DIABETES 
MELLITUS
HTN CHRONIC GN
YES
- YES
YES HD SRMC YES YES
YES
YES PD RGGGH - YES
YES PD RGGGH YES
YES HD  PD RGGGH - YES
YES YES
YES PD RGGGH - YES
YES PD RGGGH - YES
YES PD RGGGH
YES PD RGGGH
YES PD RGGGH - YES
YES  YES
-
YES YES
YES
YES YES
- YES
YES PD RGGGH YES YES
YES
YES YES
YES YES
YES PD, HD HD-GVMCH  PD-
RGGGH
YES YES
YES PD RGGGH - YES
- YES
- YES
- YES
YES PD RGGGH YES YES
- YES YES
YES YES  
-
YES YES
YES
YES YES
- YES YES
YES YES
 YES PD RGGGH - YES
YES
YES
YES NOT WILLING YES YES
YES YES
YES YES
YES
YES
YES
YES HD  PD RGGGH YES YES
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YES PD RGGGH YES YES
- YES
YES YES
YES PD RGGGH YES YES
YES PD RGGGH
YES YES
YES
YES YES
YES YES
YES YES 
- YES
YES YES
YES
YES YES YES
YES YES
yes yes
YES YES
YES PD RGGGH YES YES
- YES
YES
YES PD RGGGH YES YES
YES
- YES
YES YES
YES YES
YES PD RGGGH YES YES
- YES YES
YES PD RGGGH YES YES YES
- YES
YES PD RGGGH YES YES
- YES
- YES YES
YES YES
YES YES 
- YES
YES HD SRMC YES YES
YES YES
YES PD RGGGH YES
YES YES
- YES
YES
YES
YES YES
YES YES
YES
YES YES
YES
YES YES
RENAL 
REPLACEMENT 
THERAPY
HD / PD / HD AND 
PD
CENTRE DIABETES 
MELLITUS
HTN CHRONIC GN
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CHRONIC 
INTERST. 
NEPHRITIS
MYELOMA OBS. UROPATHY ISCH. 
NEPHROPATHY
OTHERS UNKNOWN 
CAUSE
YES
YES
YES
YES
YES-MULTIPLE 
MYELOMA
ADPKD
YES
YES
YES NSAID 
NEPHROPATHY
YES
Boopalan
Kondaiah
Perumal
Raja
Vasantha Kumari
Ramayi
Angusamy
Munusamy
Parvathy
Selvi
Abdul Jaffar
Ramaih
Shanthi
Savitri
Shenbagavalli
Parameshwari 
Jagadishwari
Selvam
Elizabeth
Subhamma
Poongothai
Angaiyan
Kuppammal
Panjammal
Ranganathan
Vasantha
Sakunthala 
Periasamy
Pandi 
Ramu
Chinnaponnu
Vazeer Baasha
Prakash
Vasantha
Periyasamy
Vanitha
Krishnakumari
Murugesan
Petchiyammal
Gopal
Sunthari
Saraswathi
Lakshmi
Mohammed 
Hussaun
Chinnayyan
Sambasivam
Alankaram
Egambaram
Dharman
Parthasarathy
NAME
MASTER CHART
 19
YES
YES
ADPKD
YES
?
YES
YES
?
YES
YES
CHRONIC 
INTERST. 
NEPHRITIS
MYELOMA OBS. UROPATHY ISCH. 
NEPHROPATHY
OTHERS UNKNOWN 
CAUSE
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